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Abstract
Female lupus prone NZM2410 estrogen receptor alpha (ERα) functionally deficient
(ERαKO) mice are protected from renal disease and have prolonged survival compared to
wild type (WT) littermates, however the mechanism of protection is unknown.
Plasmacytoid dendritic cells (pDCs) and type I interferon (IFN) drive lupus pathogenesis
and estrogen acting via ERα enhances both pDC development and IFN production. The
objectives for this work were to determine if ERα modulates pDC number, maturation, or
function in pre-disease NZM2410 mice as a possible protective mechanism of ERα
functional deficiency in lupus prone mice. We measured the effect of ERα functional
deficiency on spleen pDC frequency, number, maturation, activation state, and type I IFN
activity. ERα functional deficiency reduced the frequency of MHCII+ pDCs without
altering overall pDC frequency, number, or maturation state. Additionally, ERαKO
NZM2410 mice had significantly decreased numbers of pDCs expressing PDC-TREM, a
modulator of toll-like receptor (TLR) mediated IFN production. ERαKO NZM2410 mice
also had reduced endogenous spleen type I IFN activity. After in vitro TLR9 stimulation,
ERα functional deficiency significantly reduced the expression of PDC-TREM on pDCs
from both NZM2410 and C57BL/6 mice. pDCs from ERαKO mice had reduced levels of
PDC-TREM transcripts prior to TLR stimulation, suggesting that ERα signaling alters the
pDC’s potential to respond to TLR stimulation, thus ‘pre-programming’ the pDCs. Since
PDC-TREM is required for pDC TLR mediated IFN production, this finding represents a
mechanism by which ERα impacts pDC IFN production. Thus, we have identified a
significant effect of ERα functional deficiency on pDCs and type I IFN activity in predisease NZM2410 mice. We believe the modulation of PDC-TREM expression in pDCs
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and resultant type IFN activity may represent a mechanism by which ERα functional
deficiency protects NZM2410 mice from lupus like disease.
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Chapter 1: Rationale and Background
The relationship between the sex bias of systemic
lupus erythematosus and dendritic cells

Chapter 1: Rationale and Background
1.1 Rationale
Female ERαKO NZM2410 mice have prolonged survival compared to WT
NZM2410 mice [1]. The ERαKO mice survive longer because they do not develop as
severe glomerulonephritis, measured by albuminuria and renal pathology [1]. Although
the ERαKO mice do not develop clinical kidney disease, autoantibody production and
renal immune complex deposition are similar to levels in WT NZM mice [1]. These
findings suggested the primary impact of the functional loss of ERα function was on the
local tissue response to inflammation or the immune cell response to inflammatory
signals (e.g. autoantibodies and immune-complexes).
Dendritic cells (DCs) are activated by immune-complexes and act as a bridge
between the innate and adaptive immune responses [2]. DCs consist of two major
subsets, the classical DC (cDC) and plasmacytoid DC (pDC). In lupus, DCs (both pDCs
and cDCs) impact disease pathogenesis and progression [3, 4]. Mechanistically, dendritic
cells (DCs) express Fc receptors, which bind and subsequently internalize immunecomplexes [2]. The nuclear material (e.g. DNA and RNA) in lupus autoantibody
containing immune-complexes stimulates endosomal toll-like receptors (TLRs) [2]. TLR
stimulation results in DC activation and cytokine production, which in turn activates T
and B cells in an amplification loop of inflammation [2].
pDCs are of particular interest in SLE because they produce the type I IFNs. Type
I IFN signature genes are elevated in patients with SLE and the levels correlate with
disease activity [5]. Furthermore, IFN therapy can induce a lupus like syndrome as a side
effect. Studies in lupus prone mice have further demonstrated the importance of type I
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IFNs and pDCs in disease [5]. The absence or blockade of type I IFN ameliorates disease
in multiple mouse models [6-8]. Additionally, both partial and transient absence of pDCs
prevents clinical disease in mouse models of lupus [9, 10].
In addition to pDCs being central in lupus pathogenesis, estrogen and ERα
modulate pDC development and function [11-14]. Estrogen influences DC development
and function primarily via ERα [12, 14]. Estrogen via ERα alters both Flt3L and GMCSF mediated bone marrow derived in vitro DC development [11]. We previously
published that ERα deficient GM-CSF mediated bone marrow derived DCs, from lupusprone mice, are less responsive to TLR stimulation in vitro, consistent with previous
studies in non-autoimmune mice [15]. Regarding type I IFN, long-term exposure to in
vivo estrogen, via ERα, enhances the type I IFN response of human and murine pDCs in
response to TLR stimulation [16]. Given, ERα’s role in pDC development and function
we are interested in the impact of ERα signaling on pDCs in normal immunity and in
SLE.
In this work, we investigated the effect of ERα signaling in vivo and in vitro on
pDC number, development, activation, and function in B6 and NZM2410 mice before
and after the development of lupus like disease.
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1.2 Hypothesis
I hypothesized that ERα signaling positively impacted pDC number and
activation in pre-disease NZM2410 lupus prone mice.

Diagram I

Hypothesis

Myeloid
Progenitor
Activated
pDC

ERα

Aim I

ERα

Plasmacytoid
Dendritic Cell

Aim III

Aim II

ERα signaling increased pDC number and activity in lupus prone mice
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1.3 Background
1.3.1. Lupus Pathogenesis
Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease
characterized by the presence of antinuclear autoantibodies [17]. Although SLE may
affect virtually every organ system, symptoms and organ involvement varies widely
among individuals. Common symptoms include fatigue, fever, arthritis, skin rash, and
renal disease [17]. The prevalence of SLE is 20 to 150 cases per 100,000. However,
women account for 90% of cases, making the prevalence rates in women increase to 164
to 406 per 100,000. The exact etiology of disease is unknown and is likely multifactorial
[17]. Genetic, environmental, immunologic, and hormonal factors are implicated in
disease [17]. Regarding genetics, GWAS studies have identified over 50 genetic loci
containing polymorphisms that increase risk for SLE. Of these loci, the polymorphisms in
the major histocompatibility (MHC) locus are the most common and increase the risk of
SLE most significantly [17]. Environmental factors associated with increased risk for
disease include viruses, UV light, silica dust, and medications [17]. SLE patients have
numerous immunologic abnormalities and it has proven difficult to separate
abnormalities responsible for disease from abnormalities caused by disease. One
immunological hallmark of lupus is the production of anti nuclear antibodies, which may
occur years prior to onset of clinical symptoms [17]. These antibodies bind to self-nuclear
material to form immune complexes. The immune complexes deposit in tissue and
activate both immune and stromal cells [18]. For this reason, it is tempting to attribute
tissue damage to immune complex deposition. However, the presence of immune
complexes is not the complete immunological picture, as many people with anti nuclear

!

5!

antibodies do not develop clinical symptoms of lupus [17]. Therefore a second level for
immune dysregulation must occur to induce clinical disease. This second immune
dysregulation may occur in cells of the innate immune system [18]. Innate immune cells
contribute directly to tissue injury, release cytokines, and activate autoreactive T and B
cells [18]. One mechanism by which the adaptive and innate immune cells communicate
in SLE is by innate immune cell uptake of immune complexes. The uptake of immune
complexes activates innate immune cells and perpetuates the inflammatory response.
Since autoantibody production and immune complex deposition alone are not sufficient
to cause disease, it is likely that aberrant activation of the innate immune cells by immune
complexes represents the second level of immune dsyregulation required for organ
damage.

1.3.2 SLE sex bias
SLE affects women at a nine to one ratio compared to men. Additionally, disease
incidence is highest during the reproductive years [19]. Based on this epidemiologic data,
the sex hormones and their receptors are thought to play a role in disease.

Sex hormone levels Many studies have examined levels of sex hormones in disease and
during flares. These studies have yielded contradictory results. However, a meta-analysis
concluded that female SLE patients have reduced DHEA, progesterone, and testosterone
and increased estradiol and prolactin [20]. Male patients may have increased prolactin
and possibly a reduction in DHEA. Male SLE patient’s levels of testosterone and
estrogen are normal [20].
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Estrogen Receptor expression in SLE In PBMCs from lupus patients, RNA and protein
levels of ERα are increased compared to healthy controls [21, 22]. ERβ transcripts were
decreased in SLE PBMCs compared to controls [21]. In a study of 22 female lupus
patients and 17 controls, T cells from SLE patients had a slight (non significant) decrease
in ERα and the same levels of ERβ compared to controls [23]. However, SLE T cells
expressed higher levels of calcineurin and CD154 in response to ERα and ERβ agonists
compared to controls, suggesting SLE T cells are more responsive to estrogens than
healthy T cells [23].

Exogenous estrogen The effects of exogenous estrogens can be divided into two
categories. The first category is the effect of exogenous estrogens on disease
development and the second is the effect of exogenous estrogens on disease activity.
Development of SLE: The effects of estrogen containing oral hormonal
contraceptives and hormone replacement therapy have also been controversial in disease.
The past use of estrogen containing oral contraceptive was shown to be associated with a
significant increase (1.9 fold) of developing lupus [24]. In a later case control study, a
rate ratio of 1.19 (95% CI 0.98-1.45) was associated with any use of combined oral
contraceptive (estrogen and progesterone) [25]. The greatest risk was found in newly
started short term use (<3 months) with a rate ratio of 2.52 (95% CI 1.13-5.57) [25].
Additionally, there was an increased rate of SLE in women receiving high dose of ethinyl
estradiol (50ug) compared to women receiving medium (31-49ug) and low (<30) doses of
ethinyl estradiol [25].
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SLE activity: Regarding the effect of estradiol on SLE activity, the results have
also been controversial, however, in a large double-blind prospective study the use of oral
contraceptives was found not to increase the risk of flares in women with SLE [26].
Hormone replacement therapy was not shown to increase risk of severe flares, but does
significantly increase mild/moderate disease flares [26].

SLE and menstrual cycle

Based on self-reported data, 36% of women with SLE flare prior to menses [27].
Additionally, menstrual cycle disorders are observed in 50% of SLE patients [28].

Selective estrogen receptor modulators; tamoxifen and raloxifene:
In NZB/NZW F1 mice, tamoxifen improves disease [29]. However, in a small (n=11)
human double-blind crossover trial, tamoxifen did not improve disease [30]. Regarding
raloxifene, in NZB/W F1 mice, raloxifen administration protects mice from estradiol
mediated autoreactivity [31]. In a double-blind randomized control trail of menopausal
women with SLE, raloxifene improved bone density in SLE patients without increasing
SLE activity [32]. In this study, a there was a slight, but non significant, reduction in
disease flares and activity in the raloxifene group compared to placebo [32].

Selective estrogen receptor down-regulator; Fulvestrant:
In a double-blind and placebo-controlled study, the effects of fulvestrant were studied 16
premenopausal women with moderate SLE over a 1 year period [33]. In the group
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receiving the fulvestrant, patients were able to reduce the dose of prednisone,
hydroxychloroquine, and azathioprine compared to the control group [33].

DHEA: DHEA has been studied in randomized controls trials for lupus and has been
shown to be moderately beneficial [26, 34]. The use of DHEA, current SERMs, and
SERDs are not widely accepted as a viable treatment option due to side effects and lack
of large studies.

Mouse models: In lupus mouse models, estrogen treatment accelerated disease and
androgen treatment improved disease [35]. Additionally, ovariectomized female mice had
delayed onset of disease and the castration and estrogen treatment of male mice caused
disease to progress similar to female mice [35]. In the NZB/W mice have a strong sex
bias, with the females progressing faster than male nice. The NZM2410 mice also have a
sex bias towards the female mice, however, this sex bias is weaker than the NZMB/W
background [36]. The absence of functional ERα in female NZM2410 mice reduced
kidney disease and increased survival [1]. Protection was not provided by the absence of
ERβ [1]. The absence of functional ERα or ERβ in male mice did not provide protection,
however, this may be due to the male mice not developing severe disease at the time of
sacrifice as there were trends toward decreased disease in ERalpha deficient mice (32
weeks) [1].
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1.3.3 Dendritic cell biology
The term dendritic cell (DC) encompasses two types of cells, the plasmacytoid
dendritic cell (pDC) and classical dendritic cell (cDC). Briefly, pDCs express endosomal
toll-like receptors 7 and 9 (TLRs) [37]. When the TLRs are stimulated by their ligands,
typically viral DNA/RNA, pDCs produce large amounts of type I IFNs [37]. The type I
IFN function to alert the innate and adaptive immune systems to the presence of
infection. Through this mechanism pDCs play an important role in viral immunity. The
specifics of pDC biology will be described in the following chapters. Here, we will
review the basic functions of cDCs. cDCs are best known as antigen-presenting cells that
induce a primary immune response [2]. cDCs endocytose antigens of foreign and self
origin and present these antigens to T cells via MHCI or MHCII. cDCs also express T
cell co-stimulatory molecules (CD80/86) and produce signal three cytokines (IL-12) [2].
Depending on the environment and quality of the antigen, cDCs can induce a Th1 or Th2
response or immunologic tolerance [2]. Although all cDCs function to present antigen,
the term cDC encompasses many subtypes of DCs, each with specialized function. Due
to the plasticity of DC populations, DC ontogeny is complex. Most basically, cDCs can
be diveded into five categories; Lymphoid CD8+ DCs, lymphoid CD11b+ DCs, tissue
CD103+CD11b- DCs, inflammatory CD11b+ DCs, and migratory DCs. The DC
subtypes differ in their expression of pattern recognition receptors, location, and
regulators. Lymphoid CD8+ DCs live in the lymphoid tissue (spleen) and are best known
for sampling the blood for microbial stimuli and presenting antigens (and cross
presenting) to CD8+ T cells via MHCI [38]. Tissue CD103+CD11b- DCs share the
MHCI presentation function with the lymphoid CD8+ DCs, however they live outside of
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the spleen and sample the environment of a specific tissue [35, 38]. Lymphoid CD11b+
cells also reside in the lymphoid tissue and act as a viral sensor. Upon viral stimulation,
they secrete high levels of cytokine and present antigen via MHCII [38]. Inflammatory
CD11b+ cells are thought to arise from both the DC lineage and monocyte lineage [38].
Their maturation is induced by inflammation and are present only during an active
inflammatory response [32]. Migratory DCs live in tissue and mature and migrate to the
draining lymph node upon stimulation with microbial products. They play a role in
antigen presentation and tolerance [38].

Dendritic cells in SLE
Dendritic cells are innate immune cells involved in lupus pathogenesis and lupus organ
damage.
Diagram 2 Dendritic cells in lupus pathogenesis

pDCs

express

Fc

receptors,
bind

which

to

the

Fc

regions

of

autoantibodies

in

immune complexes
[39].
immune
binds

Once

the

complex
the

Fc

Pascual et al, 2003

DCs promotes lupus pathogenesis by producing IFN alpha, presenting
self antigens, and activating T and B cells
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receptor
endocytosis

pDCs
the

immune complex. Inside the cells the nucleic acid portion of the immune complex
stimulates endosomal TLRs (TLR7/9). TLR stimulation results in activation of the pDC
to produce IFNα. The IFNα activates T, B, NK, and classical dendritic cells (cDCs) [39].
cDCs take up apoptotic cells and can inappropriately stimulate autoreactive T and B cells
[4]. Additionally, cDCs can function in the organs to facilitate tissue damage [40].
Scheme 1 from Pascual et al. summarizes the role of pDCs and cDCs in lupus
pathogenesis [4]. Although we began describing the role of pDCs in lupus pathogenesis,
it is unclear what cell type initiates the cycle of inappropriate immune activation. Since
lupus pathogenesis involves multiple levels of immune dysregulation, disease is probably
initiated/perpetuated by dysfunction in multiple cells types.
DC dysfunction has been noted in lupus prone animals [41]. Additionally, DC
dysfunction is noted in human SLE. Although the conclusions from these studies are
complicated by differences in DC isolation and culture systems, cDC and pDC
abnormalities in cytokine production, activation, and number are present in SLE patients
(addressed in chapters 2 and 3). The requirement of DCs for disease progression in mice
was shown by the deletion of DCs in multiple lupus prone mouse strains [3, 9, 10]. In
MRL/lpr mice, the constitutive deletion of CD11c+ cells (cDCs and pDCs) prevented
renal damage [3]. Although the deletion of CD11c+ cells protected the mice from clinical
manifestations of lupus (i.e. renal damge), renal immune complex deposition was
unchanged in the DC deficient animals compared to controls [3]. Therefore, DCs likely
play a role in perpetuating organ damaged caused by immune complexes without
hindering the production of autoantibodies or the deposition of immune complexes.
Recently, two papers have shown the deletion of pDCs alone ameliorated disease in lupus
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prone mice. Both the transient deletion of pDCs and the haplodeficiency of pDCs reduced
disease in lupus prone mice [9, 10]. These deletion studies in mice have confirmed the
importance of pDCs in lupus pathogenesis.

Plasmacytoid Dendritic Cells in SLE
Plasmacytoid dendritic cells (pDC) impact lupus pathogenesis [42]. In SLE,
autoantibodies form immune complexes with self nucleic acids. pDCs take up the
immune complexs via Fc Receptors and respond to the self nucleic acids in the immune
complexes primarily through toll-like receptors (TLRs) [16]. Once the TLRs are
stimulated, pDCs produce inflammatory cytokines, including type I interferon (IFN).
pDCs rapidly produce type I interferon (IFN) in quantities 200 to 1,000 times more than
other cell types [43]. Other cell types including PMNs also make IFNalpha. Though on a
per cell basis, pDCs produce significantly more IFNalpha than PMNs, due to their being
significantly more PMNs than pDCs leads to uncertainty regarding the contribution of
one cell type vs another in the pathogenesis of lupus. Type I IFNs activate DCs, NK, B
and T cells to increase cytokine production and antigen presenting capacity resulting in
activation of the body’s innate and adaptive immune responses [44, 45]. Type I IFNs can
cause loss of self-tolerance as evidenced by development of a reversible drug-induced
lupus like disease in patients treated with IFNα for hepatitis C [46]. Type I IFN serum
levels are elevated in SLE and correlate with disease activity [46]. Mouse models have
solidified the importance of both type I IFNs and pDCs in disease. In lupus prone mice,
the expression of an IFN gene signature in myeloid and lymphoid cells precedes disease
onset [47]. Additionally, systemic treatment with IFNα of lupus prone mice exacerbated
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disease by inducing serve glomerulonephritis [48]. The deletion of the type I IFN
receptor protects NZB and NZM2328 lupus prone mice from disease [6, 7]. In the
NZM2328 model the disease protection provided by the absence of IFN signaling was
correlated with decrease function of cDCs [7]. In BXSB mice, which have a duplication
of the TLR7 gene, treatment with an anti-IFN-alpha/beta receptor antibody reduced
kidney disease and increased survival [8]. These human and murine studies support the
hypothesis that type I IFN signaling plays an important role in SLE. Two IFNα
monoclonal antibodies are being tested in SLE patients, sifalimumab and rantalizumab
[49]. These antibodies partially reduced IFN signature gene expression in peripheral
blood mononuclear cells and skin [49]. Additionally, sifalimumab improved skin and
joint symptoms [49]. However, sifalimumab was less effective in reducing the IFN
signature gene expression in patients with severe disease (mean SELDAI score of 11) and
similar findings were produced with rontalizumab treatment. . In the end, neither of these
drugs reached their primary endpoints and were thus “failures”. Trial design and dosing
may have overshadowed a positive drug effect. The partial effectiveness of these drugs
suggest it may be more powerful to more effectively block Type I interferon activity to
achieve therapeutic benefit.. However, more complete blockade of type I IFN signaling
may impair the ability of the body to flight viral infections such as seen with some kinase
inhibitors used in RA. Therefore, to create more effective therapies we must better
understand type I IFN signaling in SLE and the mediators of its effect.

Dendritic Cells and Estrogen
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Mouse and human immune cells express estrogen receptors. In mice, mature B
and NK cells expression both ERα and β [50]. T cells, pDCs, cDCs, and macrophages
express only ERα [50]. In humans, B cells express the highest amount of ERα [50].
pDCs, T cells, NK cells, and monocyte derived DCs express intermediate levels of ERα
[50]. Monocytes express the lowest levels of ERα [50]. ERβ is expressed by B cells and
pDCs [50].
A few studies have looked at sex differences in expression of estrogen receptors.
Monocytes from premenopausal women express less ERα compared to monocytes from
men and postmenopausal women [50]. However, no differences have been detected in T
cells, B cells, or pDCs [50].
Mouse DCs are obtained by culturing BM with either GM-CSF or Flt3L. Both
cytokines are important for DC development in vivo. GM-CSF drives DC generation
during inflammation and Flt3L generates DCs during the steady state [51]. BM cells are
cultured with GM-CSF to obtain a population of CD11chi CD11b+ DCs that resemble the
monocyte derived inflammatory DCs (iDC). BM can also be cultured with Flt3L to
Diagram 3 ERα’s impact on GMCSF mediated DC
development
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ERα positively regulates expression of MHCII, CD86, CD40
and inflammatory cytokine production by GMCSF mediated
derived DC by promoting IRF4 transcription
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system

represent

the

steady

state

DC

populations found in the
spleen

[52].

Both

of

these! culture systems are regulated by estrogen. Regarding GM-CSF driven BM DC
cultures, the addition of estradiol preferentially promotes the generation of
CD11chiCD11bint cells that express high levels of MHCII and CD86 (Scheme 2) [13].
Furthermore, estradiol signaling promotes the generation of fully functional iDCs [12].
The iDCs cultured in the absence of estradiol signaling express less MHCII and CD86
expression after TLR4 stimulation and they produce less inflammatory cytokines upon
engagement of CD40 [12] (Scheme 2). The effect of estradiol was specifically found to
be through ERα regulation of IRF4 transcription [12-14] (Scheme 2). In contrast to GMCSF BM cultures, estradiol via ERα reduces DC numbers from Flt3L driven BM DC
cultures, suggesting estradiol differently regulates each DC subset [11]. Regarding pDCs,
estradiol/ERα signaling increases pDC production of IFNα in response to TLR7/9
stimulation [16, 53]. Although, the majority of studies were carried out in B6 mice, one
study has looked into the effect of estradiol on BMDC cultures from lupus prone mice.
This study found the addition of estradiol to BMDC cultures from young (predisease)
mice reduced BMDC inflammatory responses, however, when estradiol was added to
BMDC cultures from mice with clinical disease the estradiol enhanced the inflammatory
responses [54]. This study suggests lupus disease activity impacts estradiol’s role in DC
function. However, more studies are needed to understand estrogen’s impact on dendritic
cells in the setting of autoimmunity and inflammation. Additionally, studies have almost
exclusively studied the role of estrogen in DC development and function using in vitro
culture and in vitro stimulation. Therefore, more works needs to be done to understand
how estradiol/ERα alters in vivo DC development and function.
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1.3.4 NZM2410 Mice
The NZM2410 mice were created by mating the litter mates from a NZB/WF1 cross with
NZW mice [36]. The NZM2410 mice have a weak gender bias towards female mice,
produce IgG anti-ds DNA, and die of immune complex mediated glomerulonephritis by 6
months of age [36]. The genetics of the NZM2410 mouse has been studied extensively. 3
lupus susceptibility loci were identified in the NZM mice [36]. These loci have been
individually crossed onto B6 mice to study their role in disease. Loci 1, sle1, contributes
to the production of autoreactive B and T cells and the production of autoantibodies. Sle2
causes B cell hyperactivity. Sle3 decreases levels of activation-induced cell death of
CD4+ cells [36]. Based on these studies, it was determine that the likelihood of
developing disease is dependent on the number and balance between susceptibility and
resistance alleles [36]. Variations in the murine susceptibility genes have been identified
in human SLE. Some of the alleles include complement receptor 2, SLAM family
members, and Fcyr2b [36].
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1.3.5 Model of ERα deficiency
The ERα ‘deficient’ mice used for this work and in most other studies of ERα deficiency
are not null for ERα [55]. The ERα deficient (ERαKO) mice were produced by inserting
a neo cassette into exon 2 and the mouse expresses an N terminal truncated chimeric ERα
protein

Diagram 4

activation
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lacking

the

function
domain,

1
but
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function 2 (AF-2), DNA

Cunningham, MA

binding,

and

ligand

binding

domains

[55]

(Scheme

3).

The

truncated ERα protein in

the knockout mice resembles both the endogenously expressed ERα46 splice variant and
the AF-1 null ERα mutant (Scheme 3). Both ERα46 and AF-1 null isoforms have a
functional impact in immune cells, including DCs. Seillet et al. showed that the AF-1
domain is differentially required for DC development [56]. The AF-1 domain is required
for steady state DC development and early stages of inflammatory DC development,
however, it is dispensable at later stages of inflammatory DC development [56].
Regarding the endogenously expressed ERα46 splice variant, monocyte to macrophage
transition induces ERα46’s expression, which correlates with MHCII expression on these
cells [57]. ERα46 is also expressed by human T, B and NK cells [58]. Based on this
evidence it is possible the truncated ERα protein, expressed by ERαKO mice, may have
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function and potentially impact disease as well as the immunological findings presented
in this article. As the relative contribution of the lack of an AF1 domain versus the
possible function of a truncated ERα are delineated, it is important to understand the
mechanisms by which this relative “ERα deficiency” is protective in lupus and impacts
DC activity in normal immunity and autoimmunity. Since the ERαKO is not a true
deficiency, this model will be referred to as the functionally mutated ERα.
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Chapter 2: Impact of estrogen receptor
alpha signaling on plasmacytoid dendritic
cell number
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Chapter 2: Impact of estrogen receptor α signaling on plasmacytoid dendritic cell
number
2.1 Introduction
Dendritic cell populations
During the steady state in vivo there are three DC populations in mouse lymphoid
organs. The populations are pDCs and two subsets of CD11c+ DCs (cDCs). The cDCs are
further divided into CD11b+ and CD8a+ cDCs. pDCs produce large amount of type I
IFNs in response to viral infection, CD8a+ cDCs present antigen to CD8+ T cells, and
CD11b+ cDCs produce inflammatory cytokines and present antigen to CD4+ T cells
[38]. Additionally, during the steady state there are tissue resident DCs, which function to
present antigen in the lymph node [59]. During the steady state DC differentiation is
dependent on Flt3L [52]. Endothelial cells, mast cells, T cells, and bone marrow
fibroblasts, and IFNy differentiated macrophages produce Flt3L [60-62]. However, other
cellular sources likely exist, particularly during the inflammatory state. In an
inflammatory state, GM-CSF drives the development of a different type of DC, the
inflammatory DC (iDC) [38, 51]. iDCs develop from GR-1+ monocytes and produce Il12 and induce the differentiation of antigen-specific Th1 cells [51]. GM-CSF is produced
by endothelial cells, fibroblasts, mast cells, macrophages, and T cells [63]. Bacterial
endotoxins, IL-6, IL-1 and TNFa can induced GM-CSF production [64]. Flt3L and GMCSF are used in vitro to culture DC populations from BM hematopoietic progenitor cells.
Flt3L driven cultures produce lymphoid organ steady state DCs (mDCs/CD11b+,
LDCs/CD8a+, and pDCs) and GM-CSF driven cultures produce iDCs [52]. Traditionally
Flt3L is thought to be responsible for steady state DC development and survival, as DCs
generation is impaired in Flt3L KO mice. However, recent evidence suggests Flt3L also
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impacts DC response during infection [65]. Flt3L is produced and released by mast cells
in response to infection and the Flt3L release mediates the expansion of the CD8+ cDC
subsets [65]. Furthermore Flt3L is increased in the synovial fluid and serum of
rheumatoid arthritis patients and the absence of Flt3L protects mice from developing
collagen induced arthritis [66, 67]. This finding highlights the complexity of DC
regulation in vivo and the need to study the DC populations in vivo under
inflammatory/disease conditions to best understand their function in disease.

Dendritic cells in SLE
DC populations in SLE patients have been studied, however, the results are
inconsistent. The inconsistences are likely due to differences in isolation and culture of
the DC subsets as well as confounders found in all studies of patients based on disease
severity, disease length and medications as well as individual variability. According to
multiple early studies, SLE patients have reduced numbers of blood pDCs. The blood
number are likely reduced because the pDCs have infiltrated the effected organs [5].
pDCs are found in both human lupus skin and kidney lesions [5, 68]. However, some
studies have identified normal to increased levels of pDCs in the blood from SLE patients
[41]. Regarding cDCs, studies have reported low to normal levels of cDCs in the blood of
SLE patients [7]. Difficulties in identifying and isolating human DCs confounded these
studies. Thus, new technologies and a better understanding of DC biology will help to
accurately identify and understand the role of DCs in SLE. In murine lupus, one study
reported pDC and cDC frequencies and numbers are increased in the spleen due to
increased homing to the spleen during disease [69]. Another study found increased
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CD11c+ cells in the spleens of lupus mice [70]. However, this area has not been
extensively studied and the markers used in these studies were not specific. Therefore,
more work must be done to identify DCs in lupus prone mice.

ERα and DC development
Estrogen via ERα impacts both GM-CSF and Flt3L mediated development of
DCs (Scheme 4).
Diagram 5 ERα’s impact on GMCSF and Flt3L mediated DC
development
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generated and the
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iDCs [12, 13]. In vivo, estradiol/ERα signaling also promotes the development of
CD11c+CD11b+ iDCs [51]. During culture with Flt3L ERα signaling takes on 2 roles.
The first role is to reduce numbers of hematopoietic progenitor cells [11]. The second is
to promote the development of fully functional DCs [11]. Therefore estradiol decreases
the overall number of DCs produced in Flt3L cultures and promotes the function of the
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remaining DCs. Thus, ERα signaling is important for the number and function of DCs.
However, more work is needed to understand how ERα signaling impacts DC
populations in vivo. Additionally, DC populations should be studied during inflammation,
as the role of ERα differs in the inflammatory state compared to the steady state.
Our laboratory found that ERα signaling positively impacts GM-CSF mediated
BM cultures from lupus prone mice [15]. The impact was more profound in DCs derived
from lupus prone mice compared to B6 control mice. To further understand ERα’s role in
lupus prone DC development the work presented in this paper investigates ERα’s impact
on DCs generated from Flt3L cultures from lupus prone mice and pDC populations
present in vivo both prior to and after the development of clinical disease.

Plasmacytoid dendritic cell development
pDCs develop from common DC progenitors (CDP) and common lymphoid
progenitors (CLP) that are Flt3+c-Kithigh. In addition to pDCs, CDPs also yield cDCs and
CLPs yield T, B, and NK cells [37]. No pDC specific progenitor has been identified.
Flt3L drives the proliferation and maturation of the common progenitors and the survival
of mature pDCs [37]. Interestingly, the pDCs are more sensitive to changes in Flt3L
levels compared to cDCs [37]. Flt3L signaling in pDCs has not been studied extensively,
but it likely signals through PI3K activation of mTOR [37]. pDCs are also more sensitive
to rapamycin (mTOR inhibition) than cDCs. Once pDCs develop to maturity they do not
proliferate. pDC life span is poorly understood.
Molecularly, pDC fate is determined by the expression of the basic helix-loophelix transcription factor E2-2 [71]. pDCs require E2-2 to develop and to maintain their
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pDC status [72]. If E2-2 is absent in a mature pDC they will begin to express the cDC
transcription factor Id2 and develop a cDC phenotype [72]. Mechanistically, E2-2
promotes the transcription of pDC specific genes and represses expression of cDC
specific genes [72].
pDCs develop to maturity in the BM and acquire the surface expression of the
pDC specific receptor Ly49Q [73]. Ly49Q expression denotes pDCs as mature in the BM
and is required for optimal IFNα production [74]. Once mature, the pDCs exit the BM
and populate peripheral lymphoid organs via the blood stream [75]. pDC exit of the bone
marrow is dependent on the transcription factor Runx2, which control expression of the
chemokine receptors CCR2 and CCR5 [75].
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2.2 Hypothesis
Since pDCs impact lupus pathogenesis and ERα signaling alters in vitro Flt3L
mediated pDCs development in healthy mice, I hypothesize ERα signaling impacts the
frequency, number, activation, and function of pDCs in pre-disease NZM2410 mice.
These changes in pDCs may account for the disease protection of ERα deficiency in
ERαKO NZM mice.
Diagram 6

Aim I Hypothesis

Plasmacytoid
Dendritic Cell

Myeloid
Progenitor

ERα

We hypothesize ERα signaling increases pDC number in lupus prone mice
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2.3 Results
ERα signaling increases plasmacytoid and myeloid DCs in Flt3L driven BM cultures
from NZM2410 mice

ERα impacts in vitro DC development in Flt3L driven BM cultures from B6 mice, but the
effect of ERα on Flt3L driven BM cultures from other strains and specifically lupusprone mice is not known [11, 56]. To assess the impact of ERα signaling on DC
populations in lupus prone mice, we cultured BM from WT and functionally mutated
ERα (ERαKO) female NZM2410 (NZM) mice with Flt3L to produce bone marrow
derived DCs (BMDCs). We identified the standard BMDC populations of pDC, myeloid
DC (mDC), and lymphoid DC (LDC) populations by flow cytometry. We studied post-
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Figure 1. DC populations in Flt3L
driven BMDC cultures. BM from WT
and ERαKO 10-14 week old female
NZM2410 and B6 mice was cultured
with 10% Flt3L for 7 days under low
estrogen conditions. The functional
mutant of ERα reduced the percent of
pDCs (B220 + CD11c + ) and mDCs
(CD11c + , B220 - , CD11b + ) without
altering the percent of LDCs (CD11c+,
B220-,CD11b-) obtained from the BM
cultures in both NZM (A) and B6 (C).
Flow cytometry plots representative of
3 separate experiments; totaling 6
animals per genotype (B, D). Cultures
from NZM ERαKO mice generated a
reduced cell yield and cultures from B6
ERαKO mice generation increased cell
yield compared to WT (E). Results are
expressed as the median ±IQR.
Statistical analysis performed with
Mann-Whitney analysis.

pubertal pre-disease (10-14 week) NZM mice to improve the likelihood of identifying a
change in DC populations responsible for disease development rather than a secondary
change caused by the disease environment. Only female mice were studied based on our
prior description that the functional mutation of ERα provides protection from disease in
females [1]. Additionally, we cultured the cells under low estrogen conditions, using
charcoal/dextran treated FBS in phenol red-free media to reduce variability caused by
differing levels of estrogen in FBS and the ERα stimulating capacity of phenol red. Using
this system, we found that BM cultures from ERαKO NZM mice, compared to WT
littermates,

had

a

lower

(CD11c+CD11b+B220-),

percentage

while

of

maintaining

pDCs
a

(CD11c+B220+)

similar

percentage

and

mDCs

of

LDCs

(CD11c+CD11b-B220-) (Figure 1A and B). The same trend, although to a lesser extent,
was observed in Flt3L driven BMDCs from age and sex matched B6 control mice (Figure
1C and D). This finding suggests the functional mutant of ERα reduced the total yield of
cells obtained from NZM BM cultures (Figure 1E), consistent with previous results in
GM-CSF driven cultures. We calculated total yield of cells by determining the ratio of
the number of cells recovered on day 7 of culture compared to the number cells placed in
culture on day 0. The yield of cells from cultured BMDCs was reduced in ERαKO mice
and this effect was restricted to BMDCs from NZM mice. In B6 control animals,
functional ERα signaling reduced the cell yield (Figure 1E). These data suggest the
impact of ERα signaling on in vitro Flt3L driven BMDC culture development and/or
survival is strain and/or disease specific. However, ERα’s impact on the percentage of
DC populations was consistent between NZM and B6 BMDCs. The impact of ERα
signaling on DC populations was consistent with previous findings in B6 animals [11].
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Overall, our findings suggest that ERα impacts the final stages of Flt3L driven DC
production regardless of disease status, however, ERα differentially impacts proximal
stages in Flt3L driven DC production depending on disease state.
The functional mutation of ERα increased apoptosis in Flt3L driven BM cultures from
NZM mice
To investigate the reduction in cell yield in Flt3L driven BM cultures from
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cells in Flt3L driven
BMDC cultures. BM from
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week old female
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Figure 2 cont. The total number of cells continuously increased over days 5 to 7 of culture and
the frequencies of live cells, pDCs, and cDCs remain constant between genotypes over days 5
to 7 (B). Results are expressed as the median ±IQR. Statistical analysis performed with MannWhitney analysis.
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ERαKO NZM mice, we measured the frequency of apoptotic and dead cells on day 7 of
culture. Flt3L derived BM cultures from ERαKO NZM mice had an increased frequency
of apoptotic cells (annexinV+) compared to WT cultures (Figure 2A). This finding
indicates that in Flt3L driven NZM BM cultures the functional mutation of ERα increases
apoptosis, which may explain the reduced cell yield. Since the change in apoptosis,
although significant, is small, we do not believe an increase in apoptosis accounts for the
total reduction in cell yield.! Therefore it is likely that the ERαKO cells have impaired
development, since mature DCs do not proliferate. Alternatively, lupus DCs are known to
be ‘overactive’ thus they may be reaching Flt3L induced maturation earlier than healthy
DC. As a result, we may be missing their peak development in culture by harvesting at
the same time as DCs from B6 mice. To determine if the lupus DCs were maturing early
we harvested Flt3L driven BM cultures from WT and ERαKO NZM mice at days 5, 6,
and 7 post sacrifice and measured total cell yield as well as frequency of each DC
subtype. We found that the NZM Flt3L driven BM cultures do not develop early, as day 7
had the highest cells yield (Figure 2B). Additionally, the frequency of DC populations
did not change between days, indicating that reduced cell yield is not due maturational
changes in a specific DC subtype (Figure 2B). This finding indicates that the reduction in
cell yield in NZM Flt3L driven BM cultures is not due to rapid development followed by
cell death. Instead, the reduced cell yield is likely due to both alterations in DC precursor
development and an increase in apoptotic cell death cause by the absence of functional
ERα.
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NZM mice have an altered distribution of pDCs in vivo compared to B6 controls
Figure 3
A

B
singlets

Total spleen cells

!

WT

!

Fsc-A

Live/Dead

mPDCA1

Fsc-H

Ssc-A

!

ERaKO
B220+CD11b-

live

!

!

CD11b

CD11c

!

siglecH
SiglecH

B220

Figure 3. Flow cytometry gating strategy for pDCs. Total spleen cells from a WT NZM2410
mouse. Cells were serially gated as follows, singlets to live to CD11b- B220+ to SiglecH+ (A). Spleen
cells from a WT and ERαKO female NZM2410 mouse showing mPDCA1 and SiglecH expression on
a B220+CD11b- population (B).

To determine if there was a difference in pDC populations between NZM and B6
mice, we measured pDCs frequency and number in the BM and spleens of pre-disease
(12-14 week) female NZM mice and B6 age and sex matched control mice. pDCs were
identified as (B220+, CD11b-, SiglecH+); the gating strategy is displayed in Figure 3. We
found that NZM mice had reduced frequencies and numbers of pDCs in the BM
compared to B6 mice (Figure 4A). The NZM mice, however, had increased frequencies
and numbers of pDCs in the spleen compared to B6 mice (Figure 4B). This finding
suggests that in NZM mice the pDC population is distributed differently than B6 mice,
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with more pDCs subsiding in the spleen and less remaining in the BM (their organ of
origin).

Figure 4
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Figure 4. pDC frequency and number in the BM and spleen of B6 and NZM2410 10-14 week old female mice.
Frequency and number of pDCs (B220+CD11b-SiglecH+) in BM of B6 and NZM mice (A). Frequency and number of
pDCs (B220+CD11b-SiglecH+) in the spleens of B6 and NZM mice (B). Flow cytometry plots represent data from at least
4 separate experiments, which are summarized in the graphs (C), B6 (n≥5) and NZM (n≥7). Results are expressed as the
median ±IQR. Statistical analysis performed with Mann-Whitney analysis.

We hypothesized pDCs from NZM mice exit the BM early and enter the
periphery as immature pDCs. To test this hypothesis we measured the maturity of the
spleen pDCs by measuring expression of the maturation marker Ly49Q. There was no
change in the frequency of pDCs expressing the Ly49Q maturation marker in the spleens
of NZM compared to B6 mice, indicating there is no difference in spleen pDC maturation
status in NZM mice (Figure 5B). This finding suggests the pDCs from NZM mice are not
exiting the BM as immature cells, but rather fully mature pDCs. Based on this evidence,
we hypothesized NZM mice have a reduced percent of mature pDCs in the BM due to
increased egress of mature pDCs from the BM. To test this hypothesis we measured
Ly49Q expression on BM pDCs. NZM mice have a significantly lower frequency pDCs
in the BM compared to B6 mice (Figure 5A). This finding suggest that in pre-disease
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Figure 5
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Figure 5. Frequency of Ly49Q+ pDCs in the BM and Spleens of B6 and NZM2410 10-14 week old female
mice. Frequency of Ly49Q+ pDCs (B220+CD11b-SiglecH+) in BM of B6 and NZM mice (A). Frequency and
number of Ly49Q+ pDCs (B220+CD11b-SiglecH+) in the spleens of B6 and NZM mice (B). Flow cytometry
plots represent data from at least 4 separate experiments, which are summarized in the graphs (C), B6 (n≥5)
and NZM (n≥7). Results are expressed as the median ±IQR. Statistical analysis performed with Mann-Whitney
analysis.

female NZM mice the mature BM pDC population exits the BM at a higher rate than
mature pDCs from B6 mice. The increased egress from the BM could explain the
increase of spleen pDC number in NZM mice. Additionally, since this work was
preformed in pre-disease lupus prone mice, the increase in mature peripheral pDCs may
contribute to SLE pathogenesis. Future work should investigate the mechanism of this
increased egress of mature pDCs from the BM. We also measured the number of cDCs
in the spleens of B6 and NZM2410 10-14 week old female mice. We did not see any
change in the frequency and number of cDCs in the spleens of NZM mice compared to
B6 (Figure 6). However, we did see a reduction in the intensity of MHCII staining in
NZM mice compared to B6 controls (to be discussed in chapter 2).
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Figure 6
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Figure 6. Frequency and number of cDCs in the spleens of B6 and NZM2410 10-14 week old female mice.
Frequency and number of cDCs (B220—SiglecH-CD11c+MHCII+) in the spleens of B6 and NZM mice (A). Flow
cytometry plots represent data from at least 4 separate experiments, which are summarized in the graphs (C),
B6 (n≥6) and NZM (n≥10). Results are expressed as the median ±IQR. Statistical analysis performed with
Mann-Whitney analysis.

ERα signaling did not alter the frequency of pDCs in the spleens and bone marrow of
lupus prone mice
Based on others and our in vitro data, we hypothesized functionally mutated ERα
would reduce the percent and number of pDCs in the bone marrow and spleens of predisease lupus-prone mice in vivo. To assess the impact of ERα on DC numbers in NZM
mice, we identified pDCs (CD11b-B220+siglecH+) and the cDC population (B220-,
siglecH-, CD11c+, MHCII+) in the spleens of WT and ERαKO pre-disease (10-14 week
old) female mice. In contrast to the in vitro effects of ERα, the in vivo the mutation of
functional ERα had no effect on the frequency or total number of spleen pDCs or cDCs in
either NZM (Figure 7A and Figure 8) or B6 mice (Figure 9 and Figure 10). To confirm
the accuracy of our pDC identification, as inflammation can alter the expression of the
pDC markers mPDCA1 and SiglecH, we showed that the siglecH+ cells represented a
single and overlapping population of cells with the mPDCA1+ population in the NZM
mice (Figure 3B) [76].
Since pDCs develop to maturity in the bone marrow, we also measured the
frequency and absolute number of pDCs in the bone marrow of WT and ERαKO NZM
mice. Although, ERα deficiency did not alter the percent of pDCs in the BM of the NZM
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Figure 7. pDC frequency and number in the spleens and BM of WT and ERαKO 10-14 week old
female NZM2410 mice. Frequency and number of pDCs (B220+CD11b-SiglecH+) in spleens of NZM2410
mice (A). Frequency and number of pDCs (B220+CD11b-SiglecH+) in the bone marrow of NZM2410 mice
(B). Flow cytometry plots represent data from 8 separate experiments, which are summarized in the
graphs, WT (n=20) and ERαKO (n=17). Results are expressed as the mean ±SD. Statistical analysis
performed with students T test.
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Figure 8. Frequency and number of cDCs in the spleens WT and ERαKO 10-14 week old female
NZM2410 mice. Frequency and number of cDCs (B220-SiglecH-CD11chiMHCIIhi) in spleens of NZM2410
mice (A). Flow cytometry plots represent data from 5 separate experiments (B) which are summarized in
the graphs, WT (n≥10 ) and ERαKO (n≥9). Results are expressed as the median ±SD. Statistical analysis
performed with students T test.
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mice, ERα deficiency reduced the absolute

number of BM pDCs (Figure 7B). The

reduction in pDC absolute number was due

to a decrease in the overall bone marrow

cellular yield in ERαKO mice (Figure 7B).

Despite the consistent decrease in BM
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Figure 9
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Figure 9. pDC frequency and number in the spleens and BM of WT and ERαKO 10-14 week old female B6
mice. Frequency and number of pDCs (B220+CD11b-SiglecH+) in spleens of B6 mice (A). Frequency and number
of pDCs (B220+CD11b-SiglecH+) in the bone marrow of B6 mice (B). Flow cytometry plots represent data from 4
separate experiments, which are summarized in the graphs, WT (n=7) and ERαKO (n≥5). Results are expressed
as the median ±IQR. Statistical analysis performed with Mann-Whitney analysis.
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cellularity and pDC numbers in ERαKO NZM mice, total spleen cell counts and spleen
pDC and cDC numbers were unaltered. This finding suggests the hematopoietic
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Figure 10. Frequency and number of cDCs in the spleens WT and ERαKO 10-14 week old female B6 mice.
Frequency and number of cDCs (B220-SiglecH-CD11chiMHCIIhi) in spleens of B6 mice (A). Flow cytometry plots
represent data from 4 separate experiments (B) which are summarized in the graphs, WT (n≥6 ) and ERαKO (n≥9).
Results are expressed as the median ±IQR. Statistical analysis performed with Mann-Whitney analysis.
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compartment can compensate for the decreased bone marrow cellularity, perhaps by
accelerated egress from the marrow or increased cellular life span of ERα mutant cells.
pD
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To support the hypothesis that accelerated egress of pDCs from the BM contributes to the
equal spleen pDC numbers there was a reduction in mature Ly49Q+ pDCs in the BM of
ERαKO NZM mice (Figure 11). Alternatively, overall pDCs in the periphery of ERαKO
NZM mice may be decreased, but the pDCs remain in the spleen rather than migrating to
peripheral organs impacted by disease in ERαKO mice.!
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Spleen Ly49Q%

Spleen Ly49Q #

ns

80

x106

% of pDCs

40

B

0.10

0.00
NZM WT

NZM ERαKO

NZM WT

0.08

!

x106

BM: ERaKO

BM: WT

!!

20

10

Ly49Q

NZM ERKO

0.06

% of pDC

48.3±2.5

BM Ly49Q #

BM Ly49Q%
30

0

52.1±3.94

0.05

20
0

Ssc-A

0.15

60

Spleen: ERaKO

Spleen: WT

0.20

!! p=0.0045
0.04

Ssc-A

A

18.4±1.7

11.87±8.3

0.02

! p=0.0267
NZM WT

0.00
NZM ERαKO

NZM WT

NZM ERαKO

Ly49Q

Figure 11. Frequency and number of Ly49Q+ pDCs in the spleens and BM of WT and ERαKO 10-14
week old female NZM2410 mice. Frequency and number ofLy49Q+ pDCs (B220+CD11b-SiglecH+) in
spleens of NZM2410 mice (A). Frequency and number of Ly49Q+ pDCs (B220+CD11b-SiglecH+) in the
bone marrow of NZM2410 mice (B). Flow cytometry plots represent data from 8 separate experiments,
which are summarized in the graphs, WT (n≥10 ) and ERαKO (n≥10). Results are expressed as the
median ±IQR. Statistical analysis preformed with Mann-Whitney analysis.
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ERα signaling did not alter the frequency of pDCs in the spleens of diseased NZM mice

To determine if advanced age of the NZM mice may bring out a difference in
pDC frequencies and numbers between WT and ERαKO mice, we measured spleen pDC
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populations in 22-26 week old, as the mice begin to develop proteinuria, WT and ERαKO
NZM mice. We also measured the frequency of non-pDC CD11c+ cells. Similar to the
pre-disease mice there was no change in the frequency or number of pDCs or CD11c+
cells in the ERαKO mice compared to WT mice (Figure 12). This finding suggests the
effect of the mutant ERα does not impact disease by altering spleen pDC frequency or
number.!
Figure 12
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Figure 12. Frequency and number of pDCs and CD11c+ cells in the in the spleens WT and ERαKO 22-26
week old female NZM2410. Frequency and number of pDCs (B220+CD11b-SiglecH+) in spleens old NZM2410
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Interestingly, there was a change in frequency and number of pDCs and CD11c+
cells in the spleens of the old NZM mice compared to the pre-disease NZM mice (Figure
13) Old NZM mice have reduced pDC frequency compared to young NZM mice (Figure
13). Additionally, the old NZM mice have an increase in frequency of CD11c+ cells
compared to young NZM mice (Figure 13). Regarding absolute numbers, the spleens of
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old NZM mice are enlarged, therefore there is an increase in total spleen cell count. Thus,
despite the decrease in pDC frequency there is a trend toward an increase in total number
of pDCs in the spleens of old NZM mice. There was significantly increased number of
CD11c+ cells in the spleens of old NZM mice compared to young NZM mice. This
finding suggests that DC numbers/distribution play a role in lupus pathogenesis.
Figure 13
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Figure 13. Frequency and number of pDCs and CD11c+ cells in the in the spleens of young and old female
NZM2410. Frequency and number of pDCs (B220+CD11b-SiglecH+) in spleens of young (10-14 weeks) and old
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1.3±0.18

Summary
Flt3L BMDC culture:
! BM from B6 and NZM ERαKO mice generate a reduced percent of pDCs and mDCs
! BM from B6 ERαKO mice had increased cell yield compared to B6 WT mice
! BM from NZM ERαKO mice had reduced cell yield compared to WT NZM mice.
! BM cultures from NZM ERαKO mice had a greater frequency of apoptotic cells
compared to WT NZM mice

Ex vivo pDC population
B6 versus NZM:
! NZM mice have increased numbers of spleen pDCs and reduced number of BM pDCs
compared to B6 mice. This is likely due to increased pDC egress from the BM in NZM
mice

Ex vivo pDC population; NZM WT versus NZM ERαKO:
! NZM ERαKO mice have equal number and frequency of spleen pDCs and cDCs
compared to WT NZM mice both prior to the development of clinical disease and after
the development of disease.
! NZM ERαKO mice have equal frequency, but reduced absolute number of pDCs in the
BM of NZM mice. The reduction in BM pDCs number is due to a decrease in overall BM
number.
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2.4 Discussion
ERα signaling in Flt3L driven BMDC cultures from NZM mice
ERα signaling impacts Flt3L driven BMDC cultures via two mechanisms. In BM
from B6 mice, ERα signaling negatively impacts numbers of BM progenitor cells to
reduce the total number of cells generated via this culture system [11, 51]. In the same
cultures, ERα signaling positively impacts the maturation of late DC progenitors to
increase the frequency of cDC and pDCs acquired from the cultures [51]. Therefore Flt3L
driven cultures of BM from ERαKO mice yields an increased number of cells, but a
reduced frequency of pDCs and cDCs compared to BM from ERα WT mice [11, 12].
Since DCs contribute to lupus pathogenesis, we wanted to determine if ERα signaling
also impacted Flt3L driven DC development in BM from NZM lupus prone mice.
Regarding percent of pDC and cDCs produced by cultures, we found BM from NZM
ERαKO mice yielded reduced frequencies of pDCs and cDCs, similar to results reported
in B6 mice and our own findings in B6 mice. This result suggests that, in lupus DCs, ERα
signaling positively regulates the late stage of DC development. Regarding total cell
yield, in our Flt3L of cultures of B6 BM, we found ERα signaling negatively regulated
total cell yield, similar to previous studies [11]. However, in Flt3L cultures from NZM
mice, ERα signaling positively impacted cell yield, indicating ERα signaling functions
differently in DC development when cells are obtained from lupus prone animals. We
hypothesize three possible reasons for this difference in ERα signaling between B6 and
NZM mice; BM from lupus prone mice may have differences in the number and ratios of
progenitor cell populations compared to B6 mice, BM cells from lupus prone mice may
create a different cell culture environment than BM from B6 mice, or BM progenitors
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from lupus prone mice have intrinsic genetic differences that impact ERα signaling.
Regarding the number and ratios of progenitor cell populations, it is possible the early
progenitor cells, which are negatively impacted by ERα signaling, may be reduced in
lupus BM. Therefore, ERα signaling in these cultures will not negatively impact cell
number because the ERα sensitive population of progenitors represents a smaller
proportion of the BM population. BM cell progenitor populations have not been studied
in lupus prone mice, therefore, it will be important to study these cell populations in the
future. Regarding the culture environment produced by lupus BM, it is possible BM
cultures from lupus prone mice produce an inflammatory environment due to the
hyperactivity of lupus immune cells. Additionally, the BM cells, prior to being removed
for culture exist in an inflammatory environment in the mouse. This environment could
have a pre-programming effect on the BM cells, which impacts ERα signaling in
response to Flt3L. The possibility of an inflammatory environment is important because
ERα functions differently in DCs depending on the culture conditions [56]. ERα contains
two activation functions, AF-1 and AF-2. The requirement for each of these domains
various between inflammatory and steady state DC. Although AF-1 is required for steady
state cDC development and function and early iDC development it is dispensable in
mature iDCs [56]. Based on this evidence, ERα signaling may change in the
inflammatory environment created in the BM of lupus prone mice. Another possibility
for the difference in cell yield is that BM cells and DCs from lupus prone mice have
altered genetics, which change the way ERα signaling impacts cell development. To
conclude, although ERα signaling functions similarly in DCs from B6 and NZM in some
situations (later stages of DC development) ERα signaling can also have different
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functions (early stages of DC development). Therefore we must study the role of ERα in
both the healthy and disease state in order to understand ERα’s role in immune function
during disease.

The effect of ERα signaling on pDC populations in vivo in lupus prone mice
Since ERα signaling positively impacts DC generation from BM cultures from
lupus prone mice, we hypothesized NZM ERαKO mice have fewer spleen pDCs
compared to WT NZM mice. However, we did not detect a change in pDC or cDC
frequency or number in the spleens of ERαKO mice compared to WT mice. This finding
suggests ERα signaling does not impact in vivo pDC generation in the same manner as
occurs in vitro. One possibility for the lack of change is that ERα signaling is not required
for in vivo pDC generation. However, Flt3L and GM-CSF are known to be critical for in
vivo DC generation and ERα signaling impacts these pathways of DC development,
making this scenario unlikely [51]. Another possibility is that other growth factors,
present in vivo, compensate for the lack of ERα signaling. This possibility is likely
because ERαKO mice have altered levels of estrogen, testosterone, and prolactin [1].
Changes in levels of the hormones may compensate for lack of ERα signaling therefore,
this possibility should be further investigated. This could be done by controlling for
hormones levels in ERαKO by ovariectomizing both WT and ERαKO mice and adding
back physiologic levels of estradiol. Alternatively, the lack of change we reported may be
due to an inability to detect the change caused by ERα signaling. Since we are not
measuring total body pDCs, our findings in the spleen may be confounded by changes in
pDC migration and distribution. Therefore, ERα’s impact may be better detected in the
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tissue. Both GM-CSF and Flt3L are produced locally during inflammation and immune
responses. Therefor ERα deficiency may impact cDC or pDC generation in the tissue.
Although this explanation is likely for cDCs, as they are known to mature in the
periphery, this is unlikely for pDCs, as they reach full maturity in the BM.
Since pDCs develop to maturity in the BM, we believe measuring pDCs in the
BM is a better measure of the ability of the ERαKO mice to generate pDCs. In the BM,
we also did not detect a change in pDC frequency in the ERαKO mice. Similar to
possibilities in the spleen, ERα’s role in pDC generation may be unnecessary or
compensated in vivo. Alternatively, the change in pDC frequency may be small or brief,
therefore making it undetectable by our methods. Like in the spleen, changes in migration
may confound our results. We hypothesized if pDCs were exiting the BM more quickly
in WT mice, thereby negating any change in pDC frequency cause by ERα signaling,
there would be less Ly49Q+ (mature) pDCs present in the BM of WT NZM mice
compared to ERαKO mice. When we measured mature pDCs in the bone marrow, we did
not see a reduction in mature pDCs in the BM of WT NZM mice. Instead, there were
slightly less mature pDCs in the BM of the ERαKO mice. Based on our findings, we
conclude ERα signaling does impact Flt3L driven DC generation in vitro, however, this
effect is not detectable in vivo. Therefore, it is unlikely that ERα signaling impacts
disease by suppressing generation of mature pDCs.
The ERαKO mice have a reduced number of total BM cells. One explanation for
the reduction in total BM cellularity is that ERα signaling is required in BM
hematopoietic progenitors for Ftl3L driven expansion. It was previously reported that
ERα deficiency impaired the renewal of hematopoietic stem-cells in the bone marrow
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[77]. Impairment in the expansion and renewal of early progenitors would explain a
reduction in total BM cell count. Alternatively, ERα signaling may impact the stromal
cell compartment. Seillet et al. showed when ERα deficiency was restricted to
hematopoietic cells, BM cellularity was not impacted [16]. This finding suggests the
reduction in BM cellularity is due to changes in bone mass (reduced space for BM), or
changes in stromal cell support of BM development. Independent of the reasoning for the
reduction in BM cellularity, the reduced number of BM cells may contribute to disease
protection in NZM ERαKO mice.

pDC numbers in NZM2410 mice compared to B6 mice
Two studies reported the deletion of pDCs protects lupus prone mice from
disease, thus, confirming their importance in disease pathogenesis [9, 10]. However,
whether they contribute to disease through abnormal numbers or function or both is not
understood. Therefore, in order to interpret our findings in the NZM ERαKO mice we
needed to first understand how pDC numbers are altered in NZM mice. Pre-disease
female NZM mice have an increased frequency and number of pDCs in the spleen
compared to age and sex matched B6 mice, indicating, changes in pDC number may
contribute to disease. This is the first report, to our knowledge, of an increase in pDCs in
the spleens of pre-disease lupus prone mice. In a 2013 publication, pDCs numbers were
increased in diseased NBW F1 mice, but not in the pre-clinical disease animals [69]. The
studies differed in stain of lupus prone mouse; however, the models are similar as mating
the NBW F1 generation created the NZM2410 mice. The major difference between the
studies was the method by which pDCs were identified. In Gleisner et al. CD11c and
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B220 were used as pDC markers [69]. Using these markers there is significant
contamination with T, B and NK cells. In our study we used CD11c B220 and the pDC
specific marker SiglecH, which is a more accurate method of identifying pDCs [78].
Therefore, there is likely a true increase in pDC frequency and numbers in the spleens of
pre-disease NZM2410 mice compared to B6 controls.
We also measured spleen pDC frequency and number in 22-26 week old NZM
mice. In this old cohort the spleen pDC frequency and numbers declined to levels
comparable to B6 mice. This finding also differs from Gleisner et al, where an increase in
pDC frequency and number, as measured by B220, was reported in diseased mice. The
pDC markers used could also explain the discrepancy between our findings. The marker
we used, SiglecH, is known to decrease on pDCs in vitro when they are stimulated with
TLR ligands (e.g. Immune complexes) [78]. Therefore, it is possible that pDCs in lupus
animals are no longer expressing siglecH. However, the use of B220 as a sole pDC
marker is not specific. Therefore, new models should be used to study pDCs in lupus
prone mice. The siglecH-eGFP mouse, which expresses GFP on pDCs even if siglecH is
down regulated, would be a good model to use in lupus [79].
If spleen pDC numbers are truly reduced in aged NZM mice this may be
explained by pDCs leaving the spleen late in the course of the disease and traveling to
sites of inflammation, which is known to occur in SLE. Alternatively, the spleen pDCs
could convert to cDCs during the course of disease. In vitro after TLR stimulation, pDCs
can convert to a cDC phenotype [80]. However, this conversion has not been
demonstrated to occur in vivo. Interestingly, in this study and other publications, cDCs
are increased in diseased mice, supporting the hypothesis DC conversion may occur.
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Further investigation is needed to understand the fate of pDCs during the progression of
lupus.
The increase in spleen pDCs in pre-diseaase NZM mice likely occurs because of
increased migration from the BM. In our work, there was a specific reduction in mature
pDCs in the BM of the NZM mice, suggesting NZM mice are not generating more pDCs
than healthy mice, but rather the migration to the periphery increases in NZM mice.
Work by Gleisner et al, supports this hypothesis, by demonstrating increased homing of
pDCs to the spleens in lupus prone mice [69]. Based on this finding, future work should
investigate expression of chemokine receptors on pDCs in SLE and the production of
these chemokines in the periphery.
We conclude that the increased numbers of pDCs in the spleens of NZM mice
likely contribute to disease pathogenesis. Furthermore, the increase is likely due to
increased migration of the pDCs to the spleen. However, the NZM WT and ERαKO mice
have equal numbers of pDCs in the spleens, indicating this is not a mechanism by which
ERα impacts disease.
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2.5 Conclusions

pDC distribution is altered in NZM mice compared to B6 mice. Furthermore, the
frequency and number of spleen pDCs is increased in the spleen prior to the development
of clinical disease. Based on this evidence and previous work in pDC deficient lupus
prone mice, we conclude pDC frequency and number likely impact progression of lupus
in NZM mice. In Flt3L driven BMDC cultures, the loss of ERα signaling negatively
impacted the generation of mature pDC and cDC populations. Furthermore, ERα
signaling differentially impacted Flt3L driven DC cultures from NZM mice compared to
B6 controls. These findings suggest ERα signaling is important for DC generation, but its
precise role varies depending on disease state. Despite the impact of ERα on in vitro DC
generation, NZM ERαKO had no change in spleen pDC frequencies, numbers, and
maturation state compared to WT NZM mice, suggesting in vivo DC generation
compensates for a lack of functional ERα signaling. Interestingly, the total BM cell count
was reduced in ERαKO mice compared to WT mice. Since this decrease was not specific
to the pDC lineage, this finding suggests functional ERα signaling may be required for
hematopoietic progenitor cell survival. Since the progenitor cells are responsive to Flt3L,
this finding may represent an in vivo role of ERα in Flt3L signaling. Additionally, the
impact of ERα signaling on total BM cell count may impact lupus pathogenesis.
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Diagram 7

Aim I Summary
ERα signaling increased pDC frequency in Flt3L driven BMDC
cultures

ERα

ERα signaling did not impact spleen pDC frequency or number

ERα signaling increased BM cell counts in pre-disease NZM mice

ERα
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2.6 Future Directions

The findings presented in this chapter suggest the NZM ERαKO mice are not
protected from disease by having impaired generation of pDCs. However, we have shown
that pDC number is altered in pre-disease mice, suggesting pDC distribution and number
impact pathogenesis. Additionally, we have shown in vitro ERα signaling is important for
pDC generation. The reason why ERα impacts FLt3L driven in vitro culture of DCs but
does not impact in vivo generation of these cells remains unanswered. The difference
could be due to changes in hormone levels in ERαKO mice. The ERαKO mice have
increased levels or estrogen and testosterone compared to WT mice. Additionally, in the
ERαKO model small amounts of mutant ERα protein lacking only the AF1 domain are
produced. Since AF1 function is dispensable for different stages of DC development, the
high levels of estradiol in the ERαKO mice may drive the function of the mutant ERα
thereby impacting in vivo pDC development and explain the discrepancy (since estradiol
levels are low in the culture conditions).
Although we did not see a difference in pDC populations specifically, we did see
a reduction in total BM cellularity in the ERαKO mice. To determine if this is a change
caused by ERα in the hematopoietic or stromal cell compartment we should study
ERαKO in a DC specific model. Although a BM transplant could be used to study this
effect in B6 mice, the NZM2410 mice a radiation resistant. Additionally, the use of AF1
and AF2 ERα mutants would also be helpful in understanding ERα’s role in disease.
Regarding the role of pDCs in lupus, independent of ERα, much work is needed
to understand the function of these cells during disease. Three areas of potential interest
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have been identified in this study. First, the migration pattern of pDCs is not understood
in lupus. Second, BM composition has not been investigated in lupus prone mice, and our
work suggests changes occur in this compartment prior to clinical disease. Third, the fate
of pDCs throughout the course of disease should be studied. Specifically, the idea of
pDC to cDC conversion needs to be studied in vivo.
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Chapter 3: Impact of estrogen receptor
alpha on plasmacytoid dendritic cell
activation
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Chapter 3 Impact of Estrogen Receptor α on plasmacytoid dendritic cell activation
3.1 Introduction
pDC activation and function
pDCs share a precursor and name with cDCs, but they function differently than
cDCs. In mice, pDCs express only the endosomal TLRs 7 and 9 [38]. Once either TLR is
stimulated, typically in response to

Diagram 8 TLR signaling in plasmacytoid
dendritic cells

viral infection, pDC produce large
amounts of type I IFNs. The type I
IFN produced by pDCs function to
activate T, B, NK cells, and other
DCs. Alternatively, pDCs can also
express high levels of MHCII,
costimulatory

molecules,

and

produce TNF and Il-16 in response
to

Gilliet, 2008
TLR 7 and 9 ligands induce IFNα, IL-6, and TNF
production and expression of costimulatory
molecules in pDCs

TLR

stimulation

[37].

Expression

of

MHCII,

costimulatory

molecules

and

production of TNF and Il-6 allow
pDCs

to

act

to

acquire

T

stimulatory capacity [81].

TLR7 and TLR9 sense ssRNA and unmethylated CpG containing DNA,
respectively. TLR9 can be stimulated by different types of CpG, included CpG type A
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and type B. Type A is a multimeric structure, which preferentially induces IFN
production and CpG type B is a monomeric structure, which induces T cell stimulatory
capacity [44]. Once stimulated both TLR7 and 9 recruit the adaptor molecule MyD88. If
CpG A is the stimulus MyD88 recruitment results in a signaling cascade leading to the
phosphorylation and nuclear transport of IRF7 and type I IFN transcription (Scheme 5)
[44]. If CpG B stimulates TLR9 MyD88 will recruit a different set of signaling
molecules, which results in NFkB activation, which promotes T cell stimulatory capacity
(Scheme5) [44].
Regulators of pDC type I IFN production are known. These include IRF7, PI3K,
Ly49Q, and PDC-TREM. The constitutive expression of IRF7 contributes to the pDC’s
ability to quickly produce large amounts of IFNs. PI3K activation of mTOR positively
regulates IFN production by promoting the nuclear localization of IRF7 [82]. Two
markers of pDC activation, specific to the IFN pathway are Ly49Q and PDC-TREM.
Ly49Q expression is acquired by pDCs as a late stage maturation marker in the bone
marrow and is required for IFN production [73, 74, 83]. PDC-TREM expression is
acquired after TLR stimulation and is also required for IFN production [84]. PDC-TREM
is associated with the cellular signaling molecule DAP12, which functions as an
activating moiety when associated with PDC-TREM, that phosphorylates PI3K and
ERK1/2 upon stimulation of pDC-TREM [84]. Stimulation of SiglecH and BST2 down
regulate the IFN response [37]. Interestingly, SiglecH also signals through DAP12,
however, in this case DAP12 acts as an inhibitory molecule [78].
Regarding antigen presentation, pDCs can express high levels of MHCII and
present antigen to stimulate T cells after TLR engagement. pDC antigen presentation
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differs from cDC antigen presentation because pDCs require TLR stimulation to present
antigen. Additionally, pDCs continuously synthesize MHCII so that they are able to
constantly sample the environment and present new antigen [85]. There is in vitro
evidence that pDCs, once stimulated by TLR ligands, convert completely to a cDC
phenotype [37]. However, there is no evidence to support this occurs in vivo or in lupus
[37].

DC activation and lupus
In SLE, there are increased levels of type I IFNs and inflammatory cytokines. The
increase in IFN levels is due to an inappropriate stimulation of pDC TLRs by immune
complexes [44]. Immune complexes from SLE patients induced type I IFN production
from pDCs. Additionally, when pDCs are deleted from lupus prone mice, IFN activity is
reduced and mice are protected from disease[10]. However, the specifics of pDC activity
during human and murine disease are not well understood. Lupus pDCs display an altered
activation status. In mice, lupus mDCs and pDCs express increased levels of CD40 and
reduced CD54 and CD80 compared to normal controls [70]. Furthermore, mDCs express
high levels of CD40 prior to the development of clinical disease [70]. Human monocytederived DCs from SLE patients express higher levels of HLA-DR and the co-stimulatory
molecules CD86 and CD80 [86, 87]. As a result, SLE mDCs also induce T cell
hyperactivity [88]. pDCs from SLE patients were found to have normal levels of
costimulatory molecules [41]. When SLE pDCs were stimulated ex vivo with CpG, pDCs
from SLE patients produced less type I IFN compared to controls [89]. The reduced IFN

!

55!

production was attributed to over stimulation with TLR ligands in SLE. Thus, more work
should be done to understand the activity levels of mDCs and pDCs in SLE.

Dendritic cells and ERα
ERα signaling also impacts DC activation and function. ERα signaling promotes
the function of pDCs and mDCs (see introduction). Regarding pDC IFN production, ERα
signaling increased pDC production of IFNα in response to TLR 9 stimulation [16]. The
increase in type I IFN production occurred when estradiol was given in vivo to humans
and mice and when it was given at the time of ex vivo TLR stimulation [16, 53]. When
mice were given estradiol in vivo prior to ex vivo TLR stimulation, the increase in IFNα
production was dependent on ERα signaling [16]. In these studies only the in vitro
stimulation of pDC activity was studied, therefore work should be done to address ERα’s
role in pDC activation in vivo. Additionally, ERα’s impact on DC activity in SLE should
be investigated.
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3.2 Hypothesis
pDC activity impacts lupus pathogenesis. Additionally, ERα signaling positively impacts
pDC activity. However, the connection between pDC activation, ERα, and lupus
pathogenesis has not been explored. We hypothesized ERα signaling positively
regulates pDC activation in pre-disease NZM2410 lupus prone mice. ERα’s role in
pDC activation in lupus prone mice may explain the disease protection of the ERαKO
mice.
Diagram 9

Aim II Hypothesis
IFN
IFN

Activated
pDC

pDC

IFN

IFN

ERα

ERα

IFN

IFN

IFN
We hypoethesize ERα signaling increases pDC activation in lupus prone mice

!

57!

3.3 Results
Absence of functional ERα reduced the frequency of activated spleen pDCs in NZM2410
mice.
Since the absence of functional ERα did not alter spleen pDC percent or number,
but does have a significant effect on disease expression, we hypothesized the lack of
functional ERα impairs the activation of pDCs in NZM mice. To determine the effect of
ERα signaling on the activation state of DCs in NZM mice, we measured the frequency
Figure 14
A

pDC: MHCII+
!

100

pDC: MHCII MFI
2500

WT!
87.4±1.9
ERαKO - - 79.2±2.0
FMO

2000

80

MFI

% of pDC

90

pDC

p=0.0071

1500
1000

70
60

B

500

! p=0.005
NZM WT

0

NZM ERαKO

NZM WT

105

cDC: MHCII MFI

ns

95

6000

90
85

C

4000
2000

80
75

NZM WT

0

NZM ERαKO

NZM WT

pDC: CD40 MFI

ns

2000

50

D

105

WT!
62.1±2.3
ERαKO - - 65.9±1.3
FMO

1000
500

NZM WT

0

NZM ERαKO

NZM WT

cDC

cDC: CD40 MFI

ns

WT!
93.8±0.69
ERαKO - - 94.0±0.59
FMO

ns

6000

95

CD40

NZM ERαKO

cDC: CD40+

100

4000

MFI

% of cDC

pDC

p=0.0401

1500

60

MFI

% of pDC

70

MHC II

NZM ERαKO

pDC: CD40+
80

40

WT!
91.9±1.5
ERαKO - - 93.1±1.3
FMO

cDC

ns

8000

MFI

%of cDC

100

MHC II

NZM ERαKO

cDC: MHCII+

90
85

2000

NZM WT

NZM ERαKO

0

NZM WT

NZM ERαKO

Figure 14. Frequency of
activated spleen pDCs
and cDCs. Frequency of
MHCII+ (A) and CD40+
(C) pDCs and median
fluorescent intensity
(MFI) of pDC MHCII (A)
and CD40 (C) in the
spleens of WT (n=13)
and ERαKO (n=10)
10-14 week old female
NZM2410 mice in 5
separate experiments.
Frequency of MHCII+ (B)
and CD40+ (D) cDCs and
MFI of cDC MHCII (B)
and CD40 (D) in the
spleens of WT (n=7) and
ERαKO (n=8) 10-14
week old female
NZM2410 mice in 3
separate experiments.
Gates for frequency were
set in each experiment
based on a fluorescence
minus one (FMO)
control. Results are
expressed as the mean
±SD or median± IQR .
Statistical analysis
performed with student’s
T test or Mann-Whitney
analysis.
Based on
normality assessment.

CD40

of pDCs and cDCs expressing major histocompatibility complex class II (MHCII) and
CD40, two described markers of DC activation. MHCII expression is required for antigen
presentation and CD40 expression is necessary for T cell activation [85, 90].
Additionally, in Sle1,2,3 mice, cDCs have increased CD40 expression prior to disease
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[70]. As shown in Figures 14A and C, the absence of functional ERα reduced the
frequency of pDCs expressing MHCII, but not CD40. ERα genotype did not alter the
frequency of cDCs expressing MHCII or CD40 (Figure 14B and 14D). The reduced
frequency of MHCII+ pDCs was restricted to the NZM mice, as MHCII expression on
pDCs from B6 mice was not altered by the functional deficiency of ERα (Figure 15).
These findings suggest ERα specifically impacts pDC activation during disease.!
Figure 15
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Figure 15. Frequency of activated spleen pDCs in B6 mice. Frequency of MHCII+ pDCs (A) in
the spleens of WT (n=9) and ERαKO (n=12) 10-14 week old female B6 mice in 4 separate
experiments. Gates for frequency were set in each experiment based on a fluorescence minus
one (FMO) control. Results are expressed as the mean ±SD. Statistical analysis performed with
Mann-Whitney analysis.

NZM mice have reduced DC MHCII expression compared to B6 control mice

Since ERα altered the frequency of MHCII+ pDC in NZM mice, we compared
MHCII expression in NZM mice to B6 mice to understand how disease impacts DC
MHC II expression. Independent of ERα, there was a reduced frequency of MHCII+
pDCs in NZM mice compared to B6 controls (Figure 15). We also detected an increased
frequency of MHCII+ cDCs in NZM mice compared to B6 controls (Figure 16).
However, there was a reduced intensity of the MHCII staining in NZM mice compared to
B6 mice (Figure 16). Thus, there is a greater frequency of MCHII + cDCs in NZM mice.
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Figure 16
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Figure 16. Frequency of activated spleen cDCs in B6 and NZM mice. Frequency of
MHCII+ cDCs (A) and the MFI of MHCII+ cDCs (B) in the spleens of B6 WT (n=9) and
NZM WT
(n=13) 10-14 week old female mice in ≥ 4 separate experiments.
Representative flow cytometry plot (C) Gates for frequency were set in each experiment
based on a fluorescence minus one (FMO) control. Results are expressed as the mean
±SD. Statistical analysis performed with a student’s T test analysis.

However, each cDC expresses less of the MHCII molecule. This finding suggests that
NZM cDCs may be down regulating MHCII as either a negative feedback mechanism or
as part of disease pathogenesis.!

Absence of functional ERα does not alter the maturation state of pDCs in NZM2410
mice.
Since ERα impacts cell number in the bone marrow and is known to alter DC
development in vitro, we wanted to ensure the pDCs from ERαKO mice reached
maturity, as lack of full maturity may explain an impaired ability to activate. We
measured the expression of Ly49Q on the spleen pDC population as a marker of pDC
maturation. Ly49Q is only expressed on fully mature pDCs and denotes their ability to
respond to TLR stimuli and produce IFNα [73, 74, 83]. In B6 mice, the majority of
spleen pDCs express this marker. The majority of spleen pDCs from NZM female mice
also expressed Ly49Q and ERα deficiency did not alter the frequency or absolute number
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of pDCs expressing Ly49Q (Figure 17). ERα deficiency thus does not alter the
maturation status of pDCs in the spleen.
Figure 17
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Figure 17. Frequency of Ly49Q+ spleen pDCs. Frequency of Ly49Q+ pDCs and MFI of Ly49Q on
pDCs in the spleens of WT (n=10) and ERαKO (n=10) 10-14 week old female NZM2410 mice in 4
separate experiments Results are expressed as the mean ±SD. Statistical analysis performed with a
t-test analysis (A,B) or Mann-Whitney analysis (C).

Absence of functional ERα reduced the frequency of PDC-TREM+ pDCs in NZM2410
mice.
Since the reduced frequency of MHCII+ pDCs was not detected in B6 mice, we
hypothesized the ERα modulates pDC response to inflammatory stimuli present in
disease, such as TLR 7 or 9 ligands. In lupus, self-nucleic acids in immune complexes
stimulate TLR7 and 9 in pDCs [91]. TLR signaling results in the activation of pDCs.
Although we studied mice pre development of autoantibodies and renal disease, it is
likely some immune abnormalities are present in the preclinical state of disease. To
determine if altered TLR signaling may be responsible for the reduction in pDC MHCII
expression, we measured the expression of the early pDC activation marker PDC-TREM.
PDC-TREM is expressed on pDCs preferentially after exposure to TLR ligands and type
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I IFNs [84]. Absence of functional ERα significantly and reproducibly reduced the
frequency of PDC-TREM+ pDCs in the spleens of NZM mice in vivo (Figure 18). pDCs
from NZM mice also had reduced MFI of PDC-TREM. This reduction was also specific
to the NZM mice, as it was not detected in pDCs from ERαKO B6 mice (Figure 19). The
percent of splenic pDCs expressing PDC-TREM was significantly higher in the WT
NZM mice versus B6 mice suggesting heightened pDC activity in lupus prone mice even
at the preclinical disease stage (Figure 20). This finding suggests the alteration in pDC
activation state may be due to an impaired response to TLR ligands in vivo in ERαKO
pDCs from NZM mice.
Figure 18
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Figure 18. Frequency of PDC-TREM+ spleen pDCs. Frequency of PDC-TREM+ pDCs and MFI of
PDC-TREM on pDCs in the spleens of WT (n=13) and ERαKO (n=9) 10-14 week old female NZM2410
mice in 6 separate experiments (A). Frequency of PDC-TREM+ pDCs and MFI of PDC-TREM on pDCs
in the spleens of WT (n=7) and ERαKO (n=8) 22-26 week old female NZM2410 mice in 3 separate
experiments (B) Results are expressed as the mean ±SD (A) or median ±IQR. Statistical analysis
performed with a t-test analysis (A) or Mann-Whitney analysis (B)

We also measured PDC-TREM expression on pDC from 22-26 week old female
WT and ERαKO NZM mice. Like, the pre-disease mice the ERαKO had a reduced
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frequency of PDC-TREM+ pDCs compared to WT pDCs (Figure 20). We did not see any
changes in PDC-TREM+ pDC frequency with advanced age, suggesting this change in
pDC activation status remains constant through the course of disease.!
Figure 19
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Figure 19. Frequency of PDC-TREM+ pDCs in the spleens B6 mice. Frequency of PDC-TREM+
pDCs and MFI of PDC-TREM on pDC in the spleens of WT (n=9) and ERαKO (n=12) 10-14 week old
female B6 mice in 4 separate experiments. Gates for frequency were set in each experiment based on
a fluorescence minus one (FMO) control. Results are expressed as the mean ±SD. Statistical analysis
performed with a Student’s T Test.

Figure 20
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Figure 20. Frequency of PDC-TREM+ pDCs in the spleens of
B6 and NZM mice. Frequency of PDC-TREM+ pDCs in the
spleens of B6 WT (n=9) and NZM WT (n=13) 10-14 week old
female mice in ≥ 4 separate experiments. Gates for frequency
were set in each experiment based on a fluorescence minus one
(FMO) control. Results are expressed as the mean ±SD. Statistical
analysis performed with a Student’s T test.
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IFN signature is reduced in ERαKO NZM mice prior to clinical disease

PDC-TREM expression is required for pDCs to produce type I IFNs. Since ERα
modulates PDC-TREM expression, we hypothesized it also impacts type I IFN activity in
lupus prone mice. To assess type I IFN activity, we measured expression of type I IFN
responsive/signature genes in the whole spleens of NZM mice. We measured genes that
are elevated in BM derived DCs of pre-disease lupus-prone mice compared to B6 mice
[47]. Using this previously validated assay, we found the absence of ERα significantly
reduced the expression of the Type I IFN signature genes Cxcl-10 and Mx1 (Figure 21).
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Figure 21. Expression
of IFN signature
genes in spleens of
pre-disease NZM WT
and ERαKO mice
Expression of Cxcl10,
Mx1, Isg15, and Irf7 in
spleens of WT (n=10)
and ERαKO (n=13)
10-14 week old female
NZM mice in ≥ 4
separate experiments.
Fold change was
calculated compared to
13 week old female B6
mouse. Results are
expressed as the
median ±IQR.
Statistical analysis
performed with
Kruskal-Wallis
analysis.

There was a trend towards reduced Isg-15, and Irf-7 expression (Figure 21).! There were
no detectable levels of IFNα or IFNβ, which can be attributed to the relative scarcity of
pDCs and cDCs in the spleen. Furthermore there was an increase in Isg-15 expression in
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Figure 22
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Figure 22. Expression of IFN signature genes
in spleens of diseased NZM WT and ERαKO
mice Expression of Cxcl10, Mx1, Isg15, Irf7, IFNγ
in spleens of WT (n=10) and ERαKO (n=13)
22-26 week old female NZM mice in ≥ 4 separate
experiments. Fold change was calculated
compared to 13 week old female B6 mouse.
Results are expressed as the median ±IQR.
Statistical analysis performed with Kruskal-Wallis
analysis.

NZM compared to B6 controls, suggesting IFN activity is increased in NZM mice
compared to B6 controls. This finding demonstrated that ERα deficiency reduced type I
IFN activity in pre-clinical disease NZM mice. We believe that the inflammatory state of
NZM female mice, even prior to clinical disease, leads to detectable differences in pDC
activation due to a key role of ERα in TLR/IFNα mediated inflammation. It is important
to note, we did not detect an increase in all IFN signature gene expressions in the spleens
from NZM mice compared to B6 controls. We chose these genes because they are
increased in BMDCs from SLE1,2,3 mice compared to B6, however, they are not
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consistently increased in ex vivo isolated spleen cells [47]. This is likely due to the
heterogeneity

of

the

spleen

cells.!
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Figure 23. Frequency
of Sca-1 + T and B
cells in the spleen of
NZM WT and ERαKO
mice Frequency of
Sca-1+ T cells DCs (A)
and Sca-1+ B cells (B)
in the spleens of WT
(n=11) and ERαKO
(n=8) 10-26 week old
female mice in ≥ 4
separate experiments.
Representative flow
cytometry plot (C).
Results are expressed
as the mean ±SD.
Statistical analysis
performed with
S t u d e n t ’ s T Te s t
analysis.

Sca-1

We also wanted to determine if advanced disease could expand the difference in
IFN signature gene expression between WT and ERαKO NZM mice, therefore we
measured the expression of the IFN signature genes in a 22-26 week old cohort of WT
and ERαKO NZM mice. In these mice we did not see a significant change in any genes.
Furthermore, there was a trend towards increased levels of mx1 and irf-7 in the spleens of
NZM ERαKO mice compared to WT controls (Figure 22). The lack of change between
IFN signature genes in the aged group of mice may be due to the immunological changes
occurring from the disease process. Additionally, we measured IFNγ expression in the
spleen, as this may contribute to IFN signature gene expression, thus accounting for
differences between genotype. However, IFNγ does not likely contribute to the IFN
signature as levels were not reduced in the spleens ERαKO compared to WT.!
To strengthen our evidence for ERα impacting type I IFN activity in NZM mice,
we chose to measure Sca-1 expression on spleen T and B cells, which is a measure of
!

66!

chronic type I IFN exposure. We did not detect any difference in the frequency of B or T
cells expression SCA-1 nor did we detect a change in MFI between the ERα genotypes
(Figure 23). We performed this test in both old (22-26 week old) NZM and young (12-14
week old) NZM mice. The lack of change could be attributed to a low sensitivity to
detect a subtle change caused by the deficiency of functional ERα.
We also measured IFN signature genes in the kidneys of diseased (22-26) week
old NZM2410 mice. We found that 1 of the WT mice had highly increased levels of the
IFN signature genes, suggesting ERα signaling plays a role in kidney IFN activity (Figure
24). This experiment was preformed only once because we could not detect pDCs in the
kidneys of NZM mice, however, kidney endothelial cells may contribute to this IFN
signature and thus could

Figure 24
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Figure 24. Expression of IFN signature genes in
the kidneys
of NZM WT and ERαKO mice
Expression of Cxcl10, Mx1, Isg15, and Irf7 in spleens
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Figure 25. Expression of IFN
signature genes in TLR9
stimulated spleens of NZM
WT and ERαKO mice
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Expression of Ifna, Ifnb,
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ERαKO (n=5) 10-14 week old
female NZM mice after 18
hours of TLR 9 sitmulation in ≥
3 separate experiments.
Results are expressed as the
mean ±SD. Statistical analysis
performed with Kruskal-Wallis
isg15 mx1 cxcl10 analysis.
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signature gene expression between genotypes (Figure 25).
Since PDC-TREM expression is consistently reduced in pDCs from ERαKO mice
and PDC-TREM is an important regulator of pDC type I IFNα production, it is likely our
measures of type I IFN activity were not sensitive enough to detect large change between
genotypes. However, we did detect a reduction in two of the four IFN signature genes
measured in the spleens of pre-disease NZM2410 mice, suggesting IFN activity is
reduced in ERαKO mice. This reduction in IFN activity may contribute to reduced
disease activity.
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Summary
Ex vivo activation status
! Pre-disease NZM ERαKO mice have a reduced frequency of pDCs
expressing MHCII and PDC-TREM compared to WT NZM mice
! NZM mice have an increased frequency of PDC-TREM expressing pDCs
compared to B6
! In B6 mice, ERαKO does not alter PDC activation status
! Pre-disease NZM ERαKO have reduced expression of IFN signature genes in
the spleen compared to NZM WT mice
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3.4 Discussion
In pre-disease lupus prone NZM2410 mice, the functional mutant of ERα reduced
pDC activation phenotype in vivo without impacting pDC number or maturation.
Specifically, the functional mutant of ERα reduced pDC expression of PDC-TREM, a
modulator of pDC type I IFN production. The absence of functional ERα simultaneously
reduced type I IFN activity in the spleens of the pre-disease NZM mice. Given the key
role of pDCs and type I IFNs in murine models of lupus, these findings suggest that
ERα’s ability to modulate pDC activation and type I IFN activity is a mechanism by
which the functional mutation of ERα protects NZM mice from disease.
DCs from lupus patients and lupus prone mice have altered expression of
activation markers [70, 87, 93]. Our study is unique in measuring the effect of ERα
signaling on the in vivo pDC activation state in lupus prone mice without ex vivo
stimulation of the pDCs. We have identified changes in pDC activation state induced by
the absence of functional ERα signaling in NZM mice prior to the development of
clinical disease, therefore, our findings may represent a mechanism by which ERα
functional mutation protects NZM mice from disease rather than reflecting an effect of
differential disease severity. Other studies have previously reported the impact of
estrogen/ERα on DC activation after stimulation with TLR ligands. Our data is in
agreement with Douin-Echinard et al. which showed that ERα deficiency reduced TLR9
mediated MHCII expression without altering CD40 expression in BMDCs cultured from
B6 mice [12]. Alternatively, in Li et al. the addition of estradiol at the time of TLR9
stimulation increased pDC CD40 expression, suggesting estrogen differentially affects
DC activation phenotype depending on whether the estrogen exposure/signaling is short
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(in vitro addition of estrogen) or long-term (in vivo deficiency of ERα ) [53]. The longterm deficiency of ERα signaling, both in our study and Douin-Echinard et al.
demonstrated a specific impact on pDC MHCII expression in ERα functionally deficient
cells [12]. Furthermore, the functional mutation of ERα reduced MHCII expression on
spleen pDCs from NZM mice, but not spleen pDCs from B6 controls. Therefore, ERα ’s
role in pDC activation phenotype in vivo appears either strain specific or represents an
effect of early disease in the NZM mice. One reason for this specificity could be that
ERα modulates pDC activation in response to immune stimuli present uniquely in NZM
mice (e.g. TLR7/9 ligands) [94]. Alternatively, a pDC intrinsic/genetic factor specific to
NZM mice could mediate ERα’s effect . We believe the former mechanism is most likely
given that, after in vitro TLR stimulation, ERα signaling also increased expression of
MHCII on pDCs from both NZM and B6 mice. These results suggest ERα’s effect on the
pDC activation phenotype, in response to TLR stimulation is independent of the pDC
strain background. In this study we have both confirmed that the functional mutation of
ERα impaired pDC activation phenotype and the reduction this occured in pDCs of NZM
mice prior to development of clinical disease. These findings indicate pDC abnormalities
in NZM2410 mice are an early marker of disease, which are impacted by ERα
expression.
A novel finding of our results is that the functional mutation of ERα reduced
PDC-TREM expression on spleen pDCs from pre-disease NZM mice. To our knowledge,
this is the first report of an effect of estrogen and/or ERα on PDC-TREM expression.
pDCs acquire PDC-TREM protein on the cell surface upon TLR stimulation and this
surface expression is required for pDCs to produce IFNα [84]. The reduction in PDC-
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TREM expression on pDCs from ERαKO NZM mice suggests that the absence of
functional ERα impairs activation in response to TLR signaling in vivo. Wataria et al.
showed that TLR7 and TLR9 ligands induced PDC-TREM expression and IFNα, TLR4
ligand, and PolyA stimulation alone could not induce PDC-TREM expression [84]. Since
TLR7/9 stimuli are known to be present in WT and ERαKO NZM mice (immune
complexes), but less so in B6 mice, in vivo pDC expression of PDC-TREM is likely
mediated, at least partially, by TLR signaling [1]. However, Swiecki et al. showed that
MyD88 was not required for PDC-TREM expression during HSV-1 infection, suggesting
stimuli other than the MyD88 dependent TLR7 and 9 ligands can induce PDC-TREM
expression [79]. Therefore ERα may alter PDC-TREM expression via another pDC
activation pathway, such as NOD-like receptors or RIG-I-like receptor stimulation or
more specific modulators of pDC activity, such as Ly49Q or SiglecH signaling in vivo.
The reduction in PDC-TREM expression on pDCs from NZM mice also suggests
ERα modulates the pDC type I IFN production pathway. This idea is supported by the
reduction in spleen type I IFN activity in NZM ERαKO mice. Our findings are in
agreement with Seillet et al., who showed that estradiol via ERα enhanced pDC IFN
production [16]. In Seillet et al., the deficiency of ERα prevented the estrogen mediated
pre-programming of pDCs in vivo, thereby reducing pDC IFN production in response to
TLR stimulation [16]. Our findings demonstrate a possible effector molecule through
which ERα modulates pDC type I IFN production. Like MHCII expression, the
functional mutation of ERα reduced PDC-TREM expression on pDCs from cultured
BMDCs after in vitro TLR stimulation in both BMDCs from NZM and B6 mice. Since,
after in vitro TLR stimulation, ERα deficiency impacts PDC-TREM expression in both
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strains of mice, these data suggest ERα modulation of PDC-TREM may represent both a
mechanism of disease protection and a general mechanism by which ERα impacts type I
IFN production and TLR responses.

To accurately measure type I IFN activity in lupus prone mice, without artificially
stimulating the cells, we measured the expression of type I IFN signature genes in the
spleen. The genes measured are elevated in BMDCs and certain splenocytes of predisease Sle-1,2,3 mice compared to B6 mice [47]. Expression of these genes represents
the cellular response to type I IFN stimulation, thereby the assay measures both the
amount of functional type I IFN present in an environment and the ability of the affected
cell to respond to type I IFN. We measured the IFN signature genes in total spleen cells,
thus we measured the responsiveness of total spleen to type IFN. As previously
published, IFN signature gene expression varies between spleen cell type, thus, this
variation likely impaired our ability to detect dramatic changes in IFN signature gene
levels. However, we did detect significant change in 2 of the 4 genes measured,
suggesting Erα signaling positively impacts the cycle of type I IFN production and
response. Based on the mechanics of the assay, ERα may alter the amount of type I IFN
produced, the responsiveness of spleen cells to the IFN, or both.
We hypothesized the difference in IFN signature gene expression between
genotypes would widen as diseased progressed. However, the difference between the
genotypes was reduced in diseased NZM mice. This finding may be due to immune
abnormalities occurring as disease progresses or ERα signaling impacting a negative
feedback loop. There was a trend towards increased ISG-15 in the spleens of the 22-26
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week of NZM ERαKO mice compared to NZM WT mice. ISG-15 protein is a ubiquitin
like protein that covalently attaches to target proteins [95]. Once attached ISG-15 can
regulate protein function and survival. Thus, it may be possible increased levels of ISG15 in the ERαKO negatively regulates type I IFN production as disease progresses.
Other studies have shown estrogen via ERα affects pDC production of type I IFN
[16, 53]. In Seillet et al., the treatment of post menopausal women with estradiol in vivo
induced pDCs to produce higher amounts of IFNα upon TLR stimulation [16]. Further
more, Seillet et al. showed that estradiol’s impact on IFNα production was dependent on
ERα in mice. Li et al. demonstrated that simultaneous in vitro estradiol and TLR
treatment enhanced pDC type I IFN production compared to TLR stimulation alone [53].
Although these papers argue that estradiol/ERα alters pDC IFN production through
different mechanisms, they both agree that estradiol/ERα positively impacts type I IFN
production, which may explain our findings. Although these studies address similar
questions as our work, they differ in that they focus strictly on pDC production of type I
IFNs in response to acute exposure to TLR ligand. Since the IFN signature gene
expression measures total type I IFN activity in a given environment, our data represents
type I IFNs produced by pDCs in response to endogenous stimuli present in the spleens
of lupus prone mice. This is an important differentiation, as TLR stimulation does not
fully account for the IFN signature seen in lupus prone mice [47]. Alternatively, a
different cell type could produce the IFN. Although pDCs are typically the major source
of type I IFN, viral infection can induce cDCs to produce significant amounts of type I
IFN [96]. Therefore, in the future, both pDC and cDC type I IFN production should also
be measured in the lupus prone mice.
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3.5 Conclusions

In pre-disease NZM2410 mice, ERα signaling positively impacted pDC activation
state. Since this finding is restricted to NZM2410 mice and not seen in B6 mice, ERα
signaling likely impacted pDC activation in response to disease specific stimuli.
Furthermore, ERα signaling positively impacted pDC expression of PDC-TREM, a
regulator of pDC IFNα production. ERα also positively impacted endogenous IFN
activity in NZM mice prior to the development of clinical disease. These findings suggest
ERα signaling may alter the IFN production pathway by influencing expression of PDCTREM. Since type I IFNs are critical in lupus pathogenesis, we believe ERα’s impact on
pDC and IFN activity may represent a mechanism by which the functional mutation of
ERα protects mice from disease. Additionally, we found these changes prior to the
development of clinical disease, which further supports the hypothesis that these changes
impact pathogenesis.!

Diagram 10

Aim II Summary
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ERα signaling increased endogenous pDC activation in pre-disease lupus prone mice
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3.6 Future Directions
Future work could address ERα’s role on in vivo type I IFN production. Although
we detected a change in total spleen IFN signature gene expression in the NZM ERαKO
mice we did not identify the cells producing IFN nor did we identify the cells affected by
IFN. To answer these questions we could sort pDCs and cDCs from WT and ERαKO
NZM mice. Then IFNα and IFNβ transcripts could be measured both with and without
exogenous TLR stimulation. This would determine if ERα regulates pDC IFN production
in vivo. Additionally, we can sort B, T and NK cells from the spleen and measure their
expression of IFN signature genes to determine if ERα signaling impacts their response to
endogenous IFN activity.
We looked for pDCs in the kidneys in NZM mice. However, were not able to
detect these cells by flow cytometry. Other groups have reported a lack of kidney pDCs
in mice, however pDCs are present in the kidneys in humans with SLE [79].
Additionally, we detected highly increased expression of IFN signatures genes in 1 WT
NZM mouse, but not the 2 ERαKO mice. Therefore it may be worthwhile to look into
pDCs and type I IFNs in the kidneys of WT and ERαKO NZM mice. Since resident
kidney cells produce type I IFNs in lupus, ERα may regulate kidney resident cell
production of IFN [92]. Alternatively, it is possible that pDCs infiltrate the kidney and
murine lupus, but lose traditional pDC markers. pDC markers can be lost in vitro after
TLR stimulation [78]. Thus, a lupus mouse model with a fluorescently tagged pDCs may
help determine the fate of pDCs as disease progresses. Lastly, ERα may regulate cDC
production of type I IFNs in the kidneys. cDCs are found in lupus kidneys and cDCs
have been shown to be able to produce large amounts of type I IFNs under inflammatory
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conditions [Cunningham, unpublished data] [96]. Therefore, IFN production by kidney
cDCs should be investigated.
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Chapter 4: The impact of estrogen
receptor α signaling on PDC-TREM
expression
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Chapter 4: The impact of estrogen receptor α signaling on PDC-TREM expression

4.1 Introduction
Pre-disease ERαKO NZM mice have a reduced frequency of PDC-TREM+ pDCs
compared to WT NZM mice. PDC-TREM regulates pDC IFN production, thus, likely
impacts disease activity in NZM mice. In this chapter, we will explore the mechanisms
by which ERα signaling mediates expression of PDC-TREM.

PDC-TREM
TREM, triggering receptor expressed on myeloid cells, proteins are a family of
surface receptors that function to modulate cellular responses on myeloid cells [97].
TREM proteins are expressed on dendritic cells, macrophages, osteoclasts, microglia,
monocytes, and platelets [97]. Both human and mouse cells express TREMs [97]. In
mice, TREMs 1-4 have been identified and in humans TREM proteins 1 and 2 have been
identified, however, a genomic region with similarities to mouse TREM 3 and 4 are
present [97]. TREMs function to integrate cell signals and regulate cell responses through
both inhibitory and activating mechanisms [97]. TREMs signal through the adaptor
molecule DAP12, which may contain either an ITAM or ITIM, with activating or
inhibiting functions, respectively [97]
PDC-TREM, also known as TREM-4, is the most recently described TREM
protein in mice [97]. It is expressed exclusively on pDCs and is expressed after TLR
stimulation [84]. It is not detected on naive pDC. Its surface expression, in response to
TLR stimulation, is dependent on MyD88, IFNAR, and DAP12 [84]. Once expressed on
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Diagram 11 TLR and PDC-TREM signaling
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the cell surface PDC-TREM associates with PlexinA1 and the intracellular adaptor
molecule DAP12, which contains an ITAM (activation) signaling domain [84]. Although
MyD88 is required for PDC-TREM expression induced by TLR stimulation, during
HSV1 infection PDC-TREM is expressed independent of MyD88, suggesting nonMyD88 dependent stimuli may contribute to its surface expression [79]. Although little is
known about PDC-TREM ligands, PDC-TREM associates with PlexinA1. After sub
optimal CpG treatment, treatment with the PlexinA1 ligand, sema6D treatment induces
IFNα production [84]. The concurrent stimulation with sem6D and suboptimal CpG
induces PI3K, ERK1/2, and IKKα/β phosphylation [84]. These signaling molecules are
involved in IFNα production (Scheme 6). PDC-TREM is required for CpG induced IFNα
production in Flt3L derived mouse pDCs. pDCs treated with shRNA for pdc-trem,
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produce significantly less IFNα, but continue to produce equal levels of IL-12, IL-6, and
TNFα [84].

Mammalian target of rapamycin
The mammalian target of rapamycin (mTOR) signaling promotes pDC production
of type I IFN [82, 98].

The mTOR signaling cascade is activated by

phosphatidylinositide 3-kinase (PI3K). When PI3K is activated by phosphorylation, it
activates mTOR, which results in the phosphorylation and nuclear localization of IRF7, a
critical step in pDC type I IFN production. Both TLR and PDC-TREM signaling
phosphorylate PI3K, thus both may promote mTOR activation [84, 99, 100].
Additionally, PI3K is a known target of ERα [99, 101, 102]. In epithelial and
endothelial cells, ERα binds to the p85alpha regulatory subunit of PI3K and induces
activation of PI3K and mTOR. Furthermore, the mTOR pathway is overactive in SLE. In
mice with lupus nephritis, glomerular PI3K and mTOR activity were increased compared
to healthy controls[103]. Human and murine lupus are improved by rapamycin treatment
[104-106].
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4.2 Hypothesis

pDC expression of PDC-TREM is required for IFNα production, a key cytokine
in lupus pathogenesis. Pre-disease ERαKO NZM mice have reduced frequencies of PDCTREM+ pDCs compared to pre-disease WT NZM mice, suggesting ERα signaling
impacts PDC-TREM expression. Additionally NZM mice have higher frequencies of
PDC-TREM+ pDCs compared to B6 control mice, thus expression of PDC-TREM is
associated with disease. Furthermore, ERαKO does not impact PDC-TREM levels in B6
mice, suggesting ERα’s impact on PDC-TREM expression occurs in response to disease
specific stimuli. One such stimuli is lupus immune complexes which, stimulate TLR7/9
in pDCs. I hypothesized ERα signaling promotes TLR mediated PDC-TREM
surface expression and this promotion occurs through an estradiol mediated
increase in pdc-trem RNA expression.
Diagram 12

Aim III Hypothesis
TLR ligand

Activated
pDC

pDC
ERα

We hypothesize ERα signaling increases TLR mediated PDC-TREM surface expression
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4.3 Results
ERα signaling impacts TLR mediated induction of PDC-TREM surface expression on
BM derived pDCs from NZM mice
To determine if the absence of functional ERα signaling impairs PDC-TREM
expression in response to TLR stimulation, we treated BMDCs from Flt3L driven
cultures, containing a mixture of pDCs and cDCs, from WT and ERαKO NZM mice with
the TLR 9 ligand, CpG DNA, and measured pDC activation. We first confirmed that
PDC-TREM surface expression is increased 12 and 18 hours after TLR9 stimulation
(Figure

Figure 26
CpG time course
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% of pDC
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Figure 26. PDC-TREM
surface expression on
BM derived pDCs after
TLR9 stimulation.
BMDCs from WT NZM
mice were treated with
TLR9 agonist (CpG 1ug/
mL) for 6, 12, and 18
hours. PDC-TREM
expression was
measured by flow
cytometry.

26).!

Based on this
finding

we

measured
PDC-TREM
expression
after 18 hours

of TLR9 stimulation for the remainder of experiments. As shown in Figure 27A, ERα
deficiency reduced the frequency of pDCs expressing PDC-TREM. In the same cultures,
ERα deficiency also reduced the frequency of MHCII expression on both pDCs and cDCs
following TLR 9 stimulation (Figure 28). There was no induction of PDC-TREM in
unstimulated controls (Figure 27B). To determine if this finding correlated with a
reduction in inflammatory cytokine production we measured levels of Il-6, TNF-α, and
Il-12p40 in the supernatant. We did not see a change in levels of any of these cytokines
between genotypes after 18 hours of TLR 9 stimulation. (Figure 29) This finding
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Figure 27
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Figure 27. TLR ligand induced PDC-TREM expression on BM derived DCs from NZM2410 mice. BM
from WT (n=6) and ERαKO (n=6) 10-14 week old female NZM2410 mice was cultured with 10% Flt3L for 7
days under low estrogen conditions. One day 7 cells were harvested and the entire mixture of pDCs and
cDCs were plated at a concentration of 2 million/mL and stimulated with 1ug of CpG (TLR9 ligand) for 18
hours. Frequency of PDC-TREM+ pDCs (CD11c+B220+) and MFI of PDC-TREM on pDCs (A). Frequency
of PDC-TREM+ pDCs and MFI of PDC-TREM on pDCs treated with PBS control (B). Representative flow
cytometry, shaded histograms represent PBS control (C). Frequency of PDC-TREM+ pDCs from WT and
ERαKO NZM mice after TLR9, TLR 7 (loroxibine 200ug/mL), and IFNα 100IU stimulation (D). Results are
expressed as the median ±IQR. Statistical analysis performed with Mann Whitney analysis. Data obtained
in 3 separate experiments.

suggestd the change in activation status does not correlate with a change cytokine
production. Alternatively, our culture system consists of a mixture of pDCs, mDCs, and
LDCs, which may dilute any change in cytokine production cause by one cell type. To
address this issue, we sorted a pure population of Flt3L derived pDCs from B6 WT and
ERαKO to measure TLR induced cytokine production. At 5 and 18 hours we did not
detect a difference in Il-6, TNF-α, and Il-12p40 production between the genotypes
(Figure 32). This finding suggests ERα signaling does not impact TLR mediated
production of these cytokines.
Since PDC-TREM surface expression can also be induced by TLR 7 stimulation
and its expression is dependent on type I IFN signaling, we stimulated BM derived DCs
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Figure 28
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Figure 28. TLR ligand induced
MHCII expression on BM
derived DCs from NZM2410
mice.
BM from WT (n=6) and
ERαKO (n=6) 10-14 week old
female NZM2410 mice was
cultured with 10% Flt3L for 7 days
under low estrogen conditions.
One day 7 cells were harvested
and the entire mixture of pDCs
and cDCs were plated at a
concentration of 2 million/mL and
stimulated with 1ug of CpG (TLR9
ligand) for 18 hours. Frequency of
MHCII+ pDCs (CD11c+B220+) and
MFI of MHCII on pDCs (A).
Frequency of MHCII+ pDCs and
MFI of MHCII on pDCs treated
with PBS control (B). Frequency of
MHCII+ cDCs (CD11c+B220-) and
MFI of MHCII on cDCs (C).
Frequency of MHCII+ cDCs and
MFI of MHCII on cDCs treated
with PBS control (D).
Representative flow cytometry,
shaded histograms represent PBS
control (E,F) Results are
expressed as the median ±IQR.
Statistical analysis performed with
Mann Whitney analysis. Data
obtained in 3 separate
experiments.
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Figure 29. TLR ligand induced cytokine production by BM derived DCs from NZM2410 mice. BM
from WT (n=8) and ERαKO (n=6) 10-14 week old female NZM2410 mice was cultured with 10% Flt3L for
7 days under low estrogen conditions. One day 7 cells were harvested and the entire mixture of pDCs and
cDCs were plated at a concentration of 2 million/mL and stimulated with 1ug of CpG (TLR9 ligand) for 18
hours. Production of IL-6, TNF-alpha, and IL12p40 were measued by ELISA. Results are expressed as
the median ±IQR. Statistical analysis performed with Mann Whitney analysis. Data obtained in 3 separate
experiments.

with TLR 7 ligand (Loroxibine) and IFNα and measured PDC-TREM surface
expression. We found a trend towards a reduced frequency of PDC-TREM+ pDCs after
TLR 7 stimulation and no difference after IFNα stimulation (Figure 27D). This finding
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suggests ERα impacts both TLR7 and 9 mediated PDC-TREM expression. However,
ERα does not greatly impact IFNα mediated PDC-TREM expression.

ERα signaling impacts PDC-TREM expression on BM derived pDCs from B6 mice.
To determine if ERα’s effect on PDC-TREM expression was strain/disease
specific we sorted pDCs (live, CD11c+B220+CD11b-) from Flt3L driven BMDCs from
WT and ERαKO B6 mice that were age and sex matched with the NZM mice and
stimulated

the

pDCs

with

the

TLR9

ligand,

CpG

DNA.!

Figure 30
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Figure 30. TLR 9 ligand induced PDC-TREM expression on BM derived pDCs from B6 mice.
BM from WT (n=5) and ERαKO (n=6) 10-14 week old female C57/BL6 mice was cultured with 10%
Flt3L for 7 days under low estrogen conditions. One day 7 cells were harvested and pDCs (CD11c+,
B220+, CD11b-) were sorted using flow cytometry and plated at a concentration of 2 million/mL and
stimulated with 1ug of CpG (TLR9 ligand) or PBS control for 18 hours. Frequency of PDC-TREM+
pDCs and MFI of PDC-TREM on pDCs (A). Frequency of PDC-TREM+ pDCs and MFI of PDC-TREM
on pDCs treated with PBS control (B). Results are expressed as the median ±IQR. Statistical
analysis performed with Mann Whitney analysis. Flow cytometry plots are representative of data in
dot plots and shaded histograms represent PBS treated controls for each genotype (C). Data
obtained in 3 separate experiments.

In this pure pDC population, ERα deficiency also reduced PDC-TREM and MHCII
expression indicating that the reduction of these activation markers on pDCs is both cell
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intrinsic not dependent on changes in the pDCs caused by the disease state. (Figure 30
and 31). Therefore the reduction in PDC-TREM expression may represent a conserved
mechanism by which ERα impacts pDC activation and may be applicable to the
regulation

of

pDC

Figure 31
A

100

3000

60

MFI

%of pDC

models.!

p=0.0043

4000

C

2000

B6 pDC

40
1000

20
0

60

0

B6 WT

B6 ERαKO

B6 pDC: % MHCII+
no stimulation

400

B6 ERαKO

B6pDC: MHCII MFI
no stimualtion

MFI

MHCII

20

200

WT
87.6±1.3
ERaKO - - 65.6±4.0

100

0
-20

B6 WT

300

40

%of pDCs

other

B6 sorted pDC: MHCII MFI

B6 sorted pDC: MHCII+
p=0.0043

80

B

in

0
B6 WT

B6 ERαKO

B6 WT

B6 ERαKO

Figure 31. TLR 9 ligand induced MHCII expression on BM derived pDCs from B6
mice. BM from WT (n=5) and ERαKO (n=6) 10-14 week old female C57/BL6 mice was
cultured with 10% Flt3L for 7 days under low estrogen conditions. One day 7 cells were
harvested and pDCs (CD11c+, B220+, CD11b-) were sorted using flow cytometry and plated
at a concentration of 2 million/mL and stimulated with 1ug of CpG (TLR9 ligand) or PBS
control for 18 hours. Frequency of MHCII+ pDCs and MFI of MCHII on pDCs (A).
Frequency of MHCII+ pDCs and MFI of MHCII on pDCs treated with PBS control (B).
Results are expressed as the median ±IQR. Statistical analysis performed with Mann
Whitney analysis. Flow cytometry plots are representative of data in dot plots and shaded
histograms represent PBS treated controls for each genotype. Data obtained in 3 separate
experiments.

MTOR pathway activation is increased in ERαKO pDCs after TLR stimulation
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Since ERα signaling positively impacts PDC-TREM expression on pDCs, and

Figure 32
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Figure 32. TLR
ligand induced cytokine
production by BM derived pDCs from B6
mice. BM from WT (n≥6) and ERαKO (n≥6)
10-14 week old female B6 mice was cultured
with 10% Flt3L for 7 days under low estrogen
conditions. One day 7 cells were harvested and
pDCs (CD11c+, B220+) were sorted using flow
cytometry and plated at a concentration of 105
cells/mL and stimulated with 1ug/mL of CpG
(TLR9 ligand) for 5 hours. For 18 hour
stimulation the pDCs were plated at a
concentration of 2 million/mL and stimulated
with 1ug of CpG (TLR9 ligand). IL-6 and TNFalpha were measured at 5 hours and TNF-alpha
and IL12p40 were measured at 18 hours. (B).
Results are expressed as the median ±IQR.
Statistical analysis performed with Mann
Whitney analysis. Data obtained in 3 separate
experiments.
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Figure 33. TLR 9 ligand
induced PS6 expression on
BM derived pDCs from
NZM mice.
BM from WT
(n=4) and ERαKO (n=4)
10-14 week old female
NZM2410 mice was cultured
with 10% Flt3L for 7 days
under low estrogen
conditions. One day 7 cells
were harvested and plated at
a concentration of 2 million/
mL and stimulated with 1ug
of CpG (TLR9 ligand) or PBS
control for 18 hours.
Frequency of PS6+ pDCs (A),
PS6+ mDCs (B), and PS6+
LDCs (C). Results are
expressed as the median
±IQR. Statistical analysis
performed with Mann
Whitney analysis. Flow
cytometry plots are
representative of data in dot
plots and shaded histograms
represent PBS treated
controls for each genotype.
Data obtained in 2 separate
experiments.

PDC-TREM impacts impacts PI3K phosphorylation, an activator of the mTOR pathway,
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we hypothesized ERα signaling would also positively impact TLR mediated
mTOR pathway activity. To test this hypothesis we measured mTOR activity via levels
of phosphorylated S6 kinase in WT and ERαKO pDCs 18 hours after TLR 9 stimulation.
We found that ERαKO pDCs expressed more phosphorylated S6, indicating that the
mTOR pathway is more active in ERαKO pDCs and mDCs compared to WT after TLR
stimulation. We hypothesized this finding may be due to a delayed onset of mTOR
pathway activation in ERαKO. We measured mTOR activation in WT and ERαKO pDCs
at short time points, 15 and 30 mins post TLR stimulation. At these time points, pDCs do
not express phosphorylated S6. However, mDCs do expression phosphorylated 6S,
indicating this pathway is more active in the mDCs compared to pDCs. Additionally,
mDCs at 18 hours express more PS6 compared to pDCs, also suggesting this pathway is
more important in ERα signaling in mDCs compared to pDCs.

Estradiol treatment does not impact TLR mediated PDC-TREM expression
Since ERαKO pDCs expressed lower levels of PDC-TREM after TLR activation,
we hypothesized estradiol treatment may increase TLR mediated PDC-TREM expression
on pDCs. To test this hypothesis, we treated BM derived ERα+/+ pDCs with 0, 1, 2, 5, and
10nM of estradiol at the time of TLR 9 stimulation (1ug/mL). We did not detect a change
in pDC-TREM expression with any concentration of estradiol treatment (Figure 34A).
This finding indicates that at an optimal level of TLR9 stimulation (1ug/mL) increasing
estradiol levels do not impact PDC-TREM surface expression. Additionally, the addition
of estradiol alone, without TLR stimulation, does not induce the surface expression of
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Figure 34
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Figure 34. The effect of estradiol treatment on TLR 9 ligand
stimulated BM derived pDCs. BM from WT and ERαKO mice was
cultured with 10% Flt3L for 7 days under low estrogen conditions. On
day 7, cells were harvested and plated at a concentration of 2 million/mL
and stimulated with estradiol and/or CpG (TLR9 ligand) or PBS control
for 18 hours. Frequency of PDC-TREM+ BM derived pDCs obtained
from WT NZM (n=3) mice after treatment with 1ug/mL of CpG and
increasing amount of estradiol (1-10nM) (A) Frequency of PDC-TREM+
BM derived pDCs obtained from WT (n=5) and ERαKO (n=4) B6 mice
after treatment with 10nM of estradiol and low amounts of CpG (0.1 or
0.25ug/mL) (B). Data obtained in 2 separate experiments.
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PDC-TREM. The literature shows that estradiol can induce optimal DC activation in the
presence of suboptimal levels of TLR ligand. Therefore, we hypothesized estradiol may
induce an effect on PDC-TREM when TLR ligand levels are suboptimal. To test this
hypothesis we added 10nM of estradiol and 0.1 or 0.25ug/mL of TLR9 ligand to BM
derived pDCs cultures. Under these conditions we did not detect any change in the
frequency of pDCs expressing PDC-TREM with the addition of estradiol (Figure 34B).
However, we detected a slight reduction in the frequency of PDC-TREM+ pDCs with the
addition of estradiol to BMDC cultures from ERαKO B6 mice (Figure 34B). This
finding, although preliminary, suggests the ERαKO protein may act as a negative
regulator of TLR ligand induced PDC-TREM expression. This hypothesis is in support of
the finding that the ERαKO mice are protected from disease, however, the full ERα
deficient mice are not (Cunningham, manuscript in preparation).

This observation

suggests the truncated ERαKO protein may be protective in disease. Therefore a future
study examining this dominant negative mechanism may be useful. Additionally, the
summation of these experiments suggests that estradiol/ERα “preprogramming” of the
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pDCs may play a role in PDC-TREM expression.

The pre programming effect of

estradiol/ERα on pDCs IFNα production has been shown in previous studies[16].!
Exposure of BM derived pDCs to IFNα during Flt3L culture enhances the reduction of
PDC-TREM expression on ERαKO pDC.
We sorted pDCs from Flt3L ligand driven BM cultures from B6 mice and
detected a reduction in TLR mediated PDC-TREM expression on ERαKO pDCs. We also
stimulated whole Flt3L driven BM cultures from WT and ERαKO NZM mice with TLR9
ligand and detected a significant and repeatable reduction in the frequency of PDCTREM+ pDCs in cultures from ERαKO NZM mice. We then stimulated whole Flt3L
driven BM cultures from WT and ERαKO B6 mice with TLR9 ligand and did not detect
a

significant

decrease

in

PDC-TREM

expression

on

ERαKO

B6

pDCs.!
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Figure 35. TLR
ligand
induced PDC-TREM
expression on BM derived
DCs pre-treated with IFNα.
BM from WT (n≥4) and
ERαKO (n≥4) female B6 mice
was cultured with 10% Flt3L
for 7 days under low estrogen
conditions with or without
100IU of recombinant mouse
IFNα. On day 7 cells were
harvested and the entire
mixture of pDCs and cDCs
were plated at a concentration
of 2 million/mL and stimulated
with 1ug of CpG (TLR9 ligand)
(A), 200ug/mL of loroxibine
(TLR7 ligand) (B), or 100IU of
IFNα (C) for 18 hours. The
DCs were alsot reated with
1ug/mL of CpG and 100IU of
IFNα simultaneously (E).
Frequency of PDC-TREM +
pDCs (CD11c + B220 + ) was
measured with flow cytometry.
Representative flow cytometry,
histogram of TLR9 stimulated
BMDCs (D).
Results are
expressed as the median ±SD.
Statistical analysis performed
with Mann Whitney analysis.
Data obtained in 3 separate
experiments.

A major difference between the NZM and B6 Flt3L cultures is the presence of an
inflammatory state in the NZM mice, both in vitro in the culture dish and prior to culture
in the mouse. Whether the inflammatory state is actively present in the culture dish or the
precursor cells have been exposed to an inflammatory environment in vivo, in this state of
inflammation pDCs may become more sensitive to TLR stimulation. Increased sensitivity
to TLR 9 ligand may explain the difference in PDC-TREM expression between NZM and
B6 mice. Furthermore, we saw a reduction in TLR mediated PDC-TREM expression on
sorted pDCs from B6 mice. Since the sorted pDCs make up the entirety of the culture, the
cells will have a greater availability of TLR 9 ligand compared to mixed cultures. Thus,
explaining the difference between sorted and mixed pDCs cultures in TLR mediated
expression of PDC-TREM. Based on this evidence we hypothesized an inflammatory
state enhances the reduction in TLR mediated PDC-TREM expression on ERαKO pDCs.
To test this hypothesis we treated Flt3L driven BM cultures with 100U/mL of IFNα on
day 0 of culture and measured TLR and IFNα mediated PDC-TREM expression on pDCs
at day 7. We found that TLR 9 ligand, TLR 7 ligand, and IFNα treatment of BM derived
DCs treated with IFNα showed trends towards reduced PDC-TREM expression on pDCs
from ERαKO mice compared the pDCs from ERαKO mice that were not treated with
IFNα during culture (Figure 35). This finding suggests that the reduction in ERαKO pDC
PDC-TREM expression is mediated by both TLR ligands and IFNα and that both of these
signals are required for ERα’s impact on PDC-TREM expression. To determine if the
effect was because of pre-programming provided by the inflammatory environment or
was an immediate effect of IFNα signaling we treated BM derived DC cultures with both
TLR 9 ligand and IFNα for 18 hours. Under these conditions, there was no change in
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PDC-TREM expression between WT and ERαKO pDCs, indicating that IFNα’s impacts
PDC-TREM expression by ’programming’ the pDCs for sensitivity to future TLR
stimulation. Since the change in PDC-TREM expression in the IFNα pre-treated cultures
was the results of reduced expression of PDC-TREM on ERαKO pDCs rather than an
increase of PDC-TREM on WT pDCs, these findings also suggest the ERαKO protein
may act as a negative regulator of pDC activation. Given the findings in with estradiol
treatment and disease protection provided by the ERαKO, this dominant negative effect
should be studied in greater detail in the future.
ERα signaling positively regulates pdc-trem mRNA levels prior to TLR stimulation
To investigate the mechanism by which the functional mutation of ERα reduced
TLR mediated PDC-TREM we hypothesized ERα could impact three aspects of pDC
development that contribute to pDC functionality. The literature demonstrates
estradiol/ERα impacts pDC type I IFN production by ‘pre-programming’ the pDCs in
vivo to be more responsive to ex vivo TLR stimulation. Although some literature supports
a stimulatory role of estradiol at the time of TLR stimulation, our data suggests ERα
impacts PDC-TREM expression by pre-programming pDC function during development.
We investigated the impact of ERα on pDC expression of the pDC master regulator gene
E2-2, TLRs7 and 9, and PDC-TREM.
E2-2 is the master transcriptional regulator of pDC development. Without E2-2
pDCs cannot develop to maturity or produce type I IFN [71]. Furthermore, if E2-2
expression is lost in mature pDCs the cells will revert back to a conventional DC
phenotype [72]. We hypothesized ERα may impact the expression of E2-2 and thereby t!
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Figure 36. Expression of pDC genes in TLR naïve pDC. BM from
WT (n=5) and ERαKO (n=6) female 10-14 week old B6 mice was
cultured with 10% Flt3L for 7 days under low estrogen conditions. On
day 7 cells were harvested and pDCs (CD11c+B220+) cells were sorted
via flow cytometry. The cells were immediately processed for RNA
extraction and transcript levels were measured by qPCR The
transcripts measured were E2-2 (A), TLR9, TLR7, IFNAR (B), PDCTREM, and DAP12 (C). Results are expressed as the median ±IQR.
Statistical analysis performed with Mann Whitney analysis. Data
obtained in 3 separate experiments.
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he overall phenotype of the pDCs. To test this hypothesis we measured levels of E2-2
transcripts in Flt3L derived pDCs from WT and ERαKO B6 mice. E2-2 transcript levels
were equal in WT and ERαKO pDCs (Figure 36 A). This finding suggests ERαKO pDCs
develop into fully mature pDCs. This finding also establishes that ERαKO, although
important in pDC development, does not impact the overall pDC phenotype of cells
produced by the Flt3L culture.
We hypothesized ERαKO pDCs are less responsive to TLR ligands because they
express reduced levels of TLR 7/9 and IFNα receptor (IFNAR). To test this hypothesis
we measured the levels of the transcripts for these receptors in BM derived pDCs from
WT and ERαKO B6 mice. There was no difference in transcript levels of TLR7, TLR9,
or IFNAR detected in between WT and ERαKO pDCs (Figure 36B). Since reliable
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Figure 37
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Figure 37. Expression of pDC genes after TLR stimulation. BM from
WT (n=6) and ERαKO (n=6) female 10-14 week old B6 mice was
cultured with 10% Flt3L for 7 days under low estrogen conditions. On
day 7 cells were harvested and pDCs (CD11c+B220+) cells were
sorted via flow cytometry. The sortd cells were plated at a concentration
of 5x105/mL and stimulated with TLR9 ligand (CpG 1ug/mL) for 5
hours. The cells were immediately processed for RNA extraction and
transcript levels were measured by qPCR The transcripts measured
were PDC-TREM, DAP-12 (A), IFNα and IFNβ (B), and IRF 7 (C).
Results are expressed as the media ±IQR. Statistical analysis
performed with Mann Whitney analysis. Data obtained in 3 separate
experiments.

antibodies for TLR7 and 9 are not available this finding provides the best evidence that
ERα does not impact TLR7/9 expression in pDCs.
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Since PDC-TREM expression was reduced in ERαKO pDCs compared to WT
pDCs after TLR stimulation we hypothesized the ERαKO pDCs have less transcripts of
PDC-TREM and PDC-TREM associated molecules. To test this hypothesis we measured
the transcripts of PDC-TREM and its associated signaling molecule DAP12 in BM
derived pDCs from WT and ERαKO B6 mice prior to stimulation with TLR ligands. The
ERαKO pDCs expressed lower levels of PDC-TREM mRNA compared to WT pDCs
(Figure 36C). Additionally, there was a trend of reduced DAP12 transcripts in the
ERαKO pDCs compared to PDC-TREM (Figure 36C). The reason for DAP12 and PDCTREM levels being reduced at different rates could be that DAP-12 acts a signaling
molecule for other pDCs surface receptors. Although PDC-TREM surface expression is
only detected after TLR stimulation, PDC-TREM mRNA is detected in unstimulated
pDCs [84]. Prior to TLR stimulation ERα signaling positively impacts PDC-TREM
mRNA levels and may increase the expression of he adaptor molecule DAP12. The
regulation of PDC-TREM mRNA may represent the mechanism by which ERα signaling
pre-programs pDCs to express increased levels of surface PDC-TREM after TLR
stimulation.
ERα signaling does not regulate pdc-trem mRNA levels after TLR stimulation
To determine if ERα signaling also reduced PDC-TREM mRNA levels after TLR
stimulation we measured the expression of PDC-TREM and DAP-12 in pDCs from B6
WT and ERαKO mice 5 hours after TLR stimulation. After TLR stimulation ERαKO
pDCs did not express significantly lower levels of PDC-TREM or DAP-12 transcripts
(Figure 37A) This finding suggests that ERα signaling does not likely impact PDCTREM and DAP-12 expression after TLR stimulation. We also measured express of
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IFNα and IFNβ transcript levels are the 5 hours time point post TLR stimulation. There
was no change in IFNα and IFNβ transcript levels between genotypes (Figure 37B).
Although, this finding suggest ERα signaling does not impact IFN production, the lack of
difference is likely due to the time point selected. These finding suggest ERα signaling
does not regulate PDC-TREM expression after TLR sitmulation, but rather through an
effect of naïve pDC expression of PDC-TREM transcripts prior to TLR stimulation.

Estrogen response elements in PDCTREM promoter
To determine if the PDC-TREM promoter contains estrogen receptors binding
sites, estrogen response elements (EREs), we used matinspector software to identify
EREs in the promoter of PDC-TREM. We searched for EREs located within 5,000 BPs
upstream of the PDC-TREM exon 1. The software identified 6 EREs within the PDCTREM promoter. Two of these EREs were specific for ERβ. The remaining 4 were
specific for ERα. The ERα EREs were located at position 1082, 2867, 4065, and 4706
(with 5000 being exon1) (Figure 38A). The ERE located at the position 1082 contained
the ERE core sequence GACC (Figure 38B and C). The three remaining EREs contained
the GTCA core sequence (Figure 38D and E). The EREs all contained core sequences as
well as >85% similarity with the surrounding 19bp around the core sequences (Table 1).
Based on this data, it is possible ERα binds directly to the PDC-TREM promoter.

!

97!

A

ERα.03

!

ERα.04

ERα.04

!

!

ERα.04

!

C
B

E
D

Figure 38. Potential estrogen response elements located in the PDC-TREM promoter. We identified 6 estrogen response
elements (EREs) in the 5,000bp upsteam of PDC-TREM exon 1 (A). Matinspector software was used to obtain potential
binding regions with 100% core sequence similairty and .85% matrix similarity. The matrix for ERα.03 is depicted in (B and C)
and the matrix for ERα.04 is depicted in (D and E). In C and E nucleotides in capital letters denote core sequence and
nucleotides in red represent highly conserved (60%) content.

Table 1. Estrogen Response Elements in PDC-TREM Promoter
Family

ERE
ERE
ERE
ERE
ERE
ERE

!

Matrix

ERα.03
ERα.04
ERβ.01
ERβ.01
ERα.04
ERα.04

Start
position

1064
2867
3021
3688
4065
4706

End position

Strand

1082 +
2885 +
3039 3706 4083 +
4724 -

Core sim.

Matrix sim.

1
1
1
1
1
1
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Sequence

0.826 aagaggcaatgaGACCtag
0.912 ggggGTCAggctgggctca
0.923 acagGTCAaatggccttgt
0.91 gcagGTCAccctgggagga
0.902 attgGTCAgtctgccggca
0.874 cctgGTCAgggtgggggat

Summary
-

ERα signaling positively impacts TLR mediated PDC-TREM surface expression
on BM derived pDCs from NZM and B6 mice

-

Estradiol treatment at time of TLR stimulation does not impact PDC-TREM
surface expression in WT BM derived pDCs.

-

WT and ERαKO BM derived naïve pDCs from B6 mice express equal levels of
E2-2, TLR7, TLR9, and IFNAR transcripts.

-

ERαKO BM derived naïve pDCs from B6 mice have significantly less PDCTREM transcripts and a trend towards reduced DAP-12 transcript levels
compared to WT BM derived naïve pDCs

-

Estradiol treatment and pre-treatment with IFNα reduced TLR mediated PDCTREM surface expression on BM derived pDCs from B6 ERαKO mice.
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4.4 Discussion
PDC-TREM protein is expressed on the surface of pDCs after TLR stimulation
and is not expressed on TLR ligand naïve pDCs [84]. However, in naïve pDCs PDCTREM transcripts are detectable [84]. We found that ERα signaling positively impacts
surface expression of PDC-TREM after TLR stimulation. Additionally, ERα signaling
positively impacts PDC-TREM transcript levels in TLR ligand naïve pDCs. These
findings suggest ERα signaling impacts TLR mediated PDC-TREM expression by
mediating naïve pDC’s potential to respond to TLR ligands. ERα’s impact on PDCTREM transcripts prior to TLR stimulation likely accounts for the majority of regulation
because estradiol treatment at the time of TLR stimulation does not alter PDC-TREM
surface expression. Therefore, ERα signaling likely ‘pre-programs’ a pDC’s ability to
respond to TLR ligand. The pre-programming by estradiol/ERα has been previously
reported. Seillet et al found in vivo estradiol signaling through ERα increased in vitro
TLR mediated pDC IFNα production [16]. Our results suggest that PDC-TREM
expression is likely also regulated by estradiol mediated pre-programming. Additionally,
our finding provides a possible mechanism by which ERα signaling impacts IFN
production.
Inflammation likely impacts ERα’s role in PDC-TREM expression. We reported
enhanced differences in pDC activation between WT and ERαKO pDCs

from

NZM

mice compared to B6 mice both in vivo and in vitro. In vivo, it is tempting to attribute
this enhancement to the presence of additional immune stimuli in NZM mice. However,
when pDCs are provided equal doses of TLR ligand in vitro, pDCs from WT and ERαKO
NZM mice maintain the greater differences in pDC activation compared to B6 mice. This
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finding suggests a mechanism beyond increased stimuli levels is responsible for the
difference. We hypothesized the increased inflammation in NZM mice contributes to
ERα’s impact on TLR mediated pDC activation. To test the hypothesis we used IFNα to
simulate an inflammatory environment in the culture during Flt3L mediated DC
development. We found that the addition of IFNα during culture broadened differences in
PDC-TREM expression between TLR stimulated WT and ERαKO pDC from B6 mice.
Although this finding was not significant for each individual stimuli, the trend was seen
in each stimuli. This finding suggests that inflammation enhances ERα’s role in TLR
mediated pDC activation. In the literature, evidence shows that ERα signaling impacts
inflammatory responses [56]. Although controversy exists in this field, ERα likely
enhances and represses inflammation depending on the scenario. Precisely how ERα
takes on this dual role is under investigation.
Inflammation also regulates ERα signaling. In an in vivo mouse model of joint
inflammation, affected joints had reduced levels of ERα protein compared to unaffected
joints [107]. Molecularly, in a breast cancer cell line NFkB repressed ERα and β
signaling activity and RelB via Blimp1 inhibited the synthesis of ERα [108].
Additionally, NFkB and ERα can act synergistically to regulate gene expression [108].
IFNα also impacts ERα signaling. Treatment of a breast cancer cell line with IFNα
increased levels of ER protein [109]. IFNα treatment of mouse spleen cells increased
levels of ERα transcripts and protein [110]. Since ERα singling enhances IFN production,
this finding suggests there is a positive feedback loop between ERα and IFNα signaling
[110].
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There is also evidence in DCs for inflammation altering ERα signaling. The
requirement for the AF-1 domain of ERα changes depending on if the DCs were grown
under inflammatory versus steady state conditions [56]. Also, our laboratory has
preliminary data suggesting inflammatory DCs express higher levels of ERα transcripts
compared to steady state DCs. Given this evidence, it is possible IFNα enhances the
pDC’s ability to respond to inflammatory stimuli and our data suggests IFNα enhances
the pDC’s ability to expression PDC-TREM after TLR stimulation.
The ERαKO mouse is not a model of complete ERα deletion. Rather, it expresses
low levels of a mutant ERα protein that lacks the AF1 domain, but maintains the DNA
binding, ligand binding, and AF2 domain. This mutant protein resembles both the
naturally expressed ERα 46 spice variant and the engineered AF1 mutant (Diagram 3).
Our data suggests the mutant ERαKO protein may impact pDC activation. When DCs
were pre-treated with IFNα, the difference in PDC-TREM expression increase between
genotypes. The increase was a result of ERαKO pDCs expressing reduced levels of PDCTREM in response to IFNα pre-treatment. Additionally, estradiol treatment did not
impact WT pDC expression of PDC-TREM, but it did reduce PDC-TREM expression on
ERαKO pDCs. This evidence suggests ERαKO mutant protein may be reducing pDC
activation status. Alternatively, the ERαKO pDCs could be less responsive to TLR
stimulation because of the hormonal milieu in the mice. The ERαKO mice have
significantly higher estrogen and testosterone levels compared to WT mice [1]. Increases
in these hormones could provide an anti inflammatory effect. Therefore this possibility
should be investigated. However, our laboratory has found that these changes in hormone
levels are not responsible for disease protection in the ERαKO mice. When the hormone
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levels were normalized in ERαKO NZM mice, the mice were protected from disease.
Additionally, the mice were not protected in the absence of estrogen, suggesting ERαKO
mutant protein requires estrogen for its function. Although the possibility that estrogen
signals through another receptor to protect from disease exists, our laboratory found that
the complete absence of ERα does not protect mice from disease. This evidence suggests
the presence of estrogen mediated ERαKO mutant signaling is necessary for disease
protection in NZM mice. Therefore, it is possible that the ERαKO protein is mediating
the reduction in PDC-TREM level.
Although, the presence of the natural isoform ERα46 is controversial, there is
evidence supporting its existence and function. ERα46 is expressed in human endothelial
cells and is located in the plasma membrane, cytosol, and nucleus. The plasma membrane
ERα46 mediates rapid changes in eNOS activity [111]. Furthermore, ERα46 can function
as a dominant negative to inhibit the transcriptional activities of ERα66 (classical ERα)
[112]. There is also evidence the 46KD isoform is expressed and has function in immune
cells. In human macrophages, the primary variant of ERα is the estradiol sensitive 46KD
isoform. Furthermore its levels increase with the monocyte to macrophage transition [57].
The expression of this splice variant is mediated by a different promoter than the ERα66.
In dendritic cells the engineered ERα AF1 mutant suggests the mutant ERαKO
protein may play a role in cell function. Like the AF1 mutant, the ERαKO mutant lacks
the AF1 domain. Using the mutant AF1 null ERα, the later stages of inflammatory
dendritic cells development was not impacted by a lack of AF1 domain. However, the
complete absence of ERα did impact later stages of DC development. This finding
suggests the ERα protein lacking AF1 has a function in later stages of DC development.
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Since the ERαKO protein resembles the AF1 null mutant, it may also impact late stage
DC development. All together this evidence suggests the ERαKO mutant protein may
play a role in disease protection. However, we need to strengthen our evidence for the
role of this protein in disease.
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4.5 Conclusions
ERα signaling positively impacts TLR mediated surface expression of PDCTREM. ERα signaling likely mediates this effect by pre-programming pDCs to be more
responsive to TLR stimulation through a developmental mechanism. (Scheme7). One
mechanism that could mediate this effect is by ERα signaling increasing levels of PDCTREM transcripts in TLR naïve pDCs. The increase in PDC-TREM transcripts occurs
without altered expression of TLR7, 9 or IFNAR. This finding suggests ERα signaling
impacts signaling factors downstream of TLRs to alter TLR responsiveness in a
developmental manner. It is possible the ERαKO mutant protein acts as a dominant
negative

to

cause

this

effect.
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ERα signaling increases TLR ligand naïve pDC expression of Pdc-trem and this may contribute to
increased TLR mediated PDC-TREM surface expression
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4.6 Future directions
Future work may focus on the regulation of PDC-TREM. Independent of ERα,
little is know about the regulation of PDC-TREM. Since transcripts are expressed prior to
TLR stimulation, it should be determined if TLR signaling promotes the translation or
intracellular trafficking of PDC-TREM. Once this is understood, the effect of ERα on this
process can be investigated. Since ERα signaling impacts PDC-TREM transcript levels, it
is important to understand if ERα impacts the transcription of the gene or stability of the
transcript. If ERα impacts transcription, we should determine if ERα directly regulates
the promoter or is it acts indirectly through a different transcription factor, which then
regulates gene expression.
Additionally, the possibility of mutant ERαKO protein acting as a dominant
negative should be investigated. This may be done by studying PDC-TREM levels in
ERα null mice and hormone controlled ERαKO mice. Additionally, work needs to be
done to detect this mutant protein in pDCs.
Lastly, ERα signaling impacts a vast amount of cell functions. Therefore, this
work should be put into the context of the broader investigation into ERα regulation of
immune cell function. Currently, our laboratory is exploring how ERα singling impacts
the transcriptome of dendritic cells. This work will likely yield important information
into the major cellular processes altered by ERα signaling.

!

106!

Chapter 5 Closing remarks

!

107!

Chapter 5 Closing remarks

Diagram 14
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ERα signaling increased endogenous pDC activation state and IFN activity in
pre-disease lupus prone mice
ERα signaling programs naive pDCs for increased TLR responsiveness

NZM2410 mice lacking functional ERα signaling are protected from disease. The
mechanism of disease protection is unknown. In this work we have determined that ERα
signaling altered the activation status of pDCs in NZM2410 mice prior to the
development of clinical disease without altering pDC number or maturation status.
Specifically, ERα signaling positively impacted PDC-TREM and MCHII expression in
pre-disease mice. The frequency of PDC-TREM+ pDCs is also increased in pre-clinical
disease NZM2410 mice compared to controls, suggesting that PDC-TREM expression
impacts disease pathogenesis. Simultaneously, ERα signaling positively regulated type I
IFN signaling in pre-disease NZM2410 mice. Since PDC-TREM expression is required
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for optimal type I IFN production by pDCs, ERα may regulate type I IFN activity via
PDC-TREM. Additionally, ERα’s impact on PDC-TREM expression and type I IFN
signaling may explain disease protection in NZM2410 mice lacking functional ERα
signaling.
Since ERα may impact disease by altering pDC expression of PDC-TREM, we
explored the mechanism by which this regulation of pDC activation occurs. We found
that ERα impacts TLR mediated induction of surface PDC-TREM expression in both B6
and NZM2410 mice, indicating this mechanism occurs in both in the disease and nondisease state. Furthermore, ERα signaling impacts PDC-TREM transcript levels prior to
TLR stimulation indicating ERα signaling ‘pre-programs’ pDCs to express more surface
PDC-TREM in response to TLR stimulation. Since PDC-TREM is required to type I IFN
production, this finding may represent a mechanism by which ERα alters pDC IFN α
production in response to TLR stimulation.
It is important to put this work into the context ERα’s role in SLE pathogenesis
and the female predominance of SLE. Regarding ERα signaling in disease pathogenesis,
ERα is a ubiquitously expressed transcription factor, which affects numerous cellular
processes. Thus, it is likely that ERα impacts disease through multiple mechanisms
including, but not limited to its impact on pDC activation. Additionally, ERα has been
shown to alter both pro and anti-inflammatory processes, suggesting ERα may impact
disease differently depending on the timing and cellular environment. Since ERα exerts
numerous effects on physiologic processes it is difficult to completely understand its
function and role in disease. Thus, our work is important because it addresses a single
and specific aspect of ERα function. To further address ERα function in disease, we will
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need to use cell specific and conditional ERα knockouts and ERα mutant models.
Additionally, we need to place ERα’s impact on PDC-TREM transcript levels within the
context of ERα’s impact on the entire transcriptome to fully understand ERα’s role in DC
‘pre-programming’. Future work will address these issues. Regarding the female
predominance of disease, the mechanism studied in this work along with other work in
our laboratory can be translated into human studies. The human studies will allow us to
explore how ERα contributes to the SLE sex bias.
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Chapter 6 Materials and Methods
Mice: ERα deficient (ERαKO) mice on the C57BL/6 background (kind gift of Dr. Ken
Korach, NIEHS, RTP, NC) were backcrossed for 12 generations to NZM2410 mice
(Jackson Laboratory, Bar Harbor, ME) and congenic status was verified as previously
described [55]. Female mice between 10 and 14 or 22-26 weeks of age were used for
these experiments. All mice were maintained at the Ralph H. Johnson VAMC Animal
Care Facility (Charleston, SC) using Institutional Animal Care and Use Committee
approved protocols #421 and #498 originally approved August 2008 and 2011
respectively.

Spleen DCs: Spleens were harvested from mice and placed on ice in RPMI-media. The
spleens were processed through 70um strainers and depleted of red blood cells with red
blood cell lysis buffer (144 mM NH4Cl and 17 mM Tris, pH 7.6). After washing in
estrogen-free RPMI-media (charcoal dextrane treated FBS in phenol red-free RPMI,
pennicillin/streptomycin, ampicillin, and L-glutamine), the cells were counted and either
placed in TRIzol (Life Technologies, Grand Island, NY) for RNA extraction or stained
for flow cytometry. For flow cytometry, 4 million cells were washed 2x in PBS and
resuspended in LIVE/DEAD Fixable Dead Cell Stain (Life Technologies) at a
concentration 50ul/million cells. Cells were washed 2x in staining buffer (0.5% BSA,
0.02% sodium azide in PBS) and treated with anti-CD16/CD32 for 5 minutes. Cells were
then stained for surface antigens with the indicated conjugated antibodies in 50ul of
staining buffer per million cells for 25minutes. All staining was performed in the dark on
ice. The cells were washed 2x in staining buffer and re-suspended in 0.3 mLs of staining
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buffer and acquired on the LSRFortessa cell analyzer (BD Biosciences, San Jose, CA).
Analysis was preformed using FlowJo software (Treestar Ind, Ashland, OR). All cells
analyzed were first identified as both singlets and live to eliminate debris and dead cells,
respectively. pDCs were identified as CD11b-, B220+, SiglecH+. Serial gating was used to
identify pDCs by identifying SiglecH+ cells in a pre-selected B220+, CD11b- population
(Supplemental figure 2). cDCs were identified as B220-, SiglecH-, CD11c+. Activation
markers were measured on these populations of DCs as indicated. Fluorescence minus
one controls were used as indicated to select gates.

Bone marrow DCs: Bone marrow was flushed from the femurs and tibias of mice and
processed through a 70um strainer and depleted of RBCs in the same manner as the
spleen. The cells were either stained for flow cytometry or cultured to obtain bone
marrow derived DCs (BMDCs). Total bone marrow was stained for flow cytometry and
analyzed in the same manner as the spleen cells.
For BMDC generation total BM was plated at a concentration of 1.5 x106 cells per
mL in estrogen-free RPMI-media with 10% supernatant from a Flt3L producing cell line
(a kind gift of Dr. Stephania Gallucci, Temple University). The BMDCS were harvested
on day 7, counted, and re-plated at a concentration of 2 x106 cells per mL in estrogen-free
RPMI for TLR ligand treatment. If indicated, pDCs were sorted from the total BMDC
population using fluorescent activated cell sorting (FACS) and plated at a concentration
of 2 x106 cells per mL in estrogen-free RPMI. Cells were sorted under sterile conditions
using the same staining protocol as the spleen cells. Samples were sorted on the BD
MoFlo Astios High Speed Cell Sorter. pDCs were identified as singlets, live, CD11b-,
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CD11c+, B220+. The pDCs or total BMDCs were treated with either PBS or CpG DNA
(TLR9 agonist) at 1ug/mL. After 18 hours, the cells were scraped from the plates and
washed in PBS to prepare for staining for flow cytometry. One million cells were stained
in the same manner as the spleen cells. BMDC populations were identified as followed;
pDCs: CD11c+. B220+, mDC: CD11c+, B220-, CD11b+, and LDCs: CD11c+, B220-,
CD11b-.

Antibodies and reagents: Fluorescent conjugated antibodies including anti-mouse
CD11c, CD11b, B220, SiglecH, mPDCA1, PDC-TREM, MHC II (I-A/I-E), and CD40
were purchased from Biolegend (San Diego, CA). PE-conjugated anti-mouse Ly49Q was
purchased from MBL International (Woburn, MA). LIVE/DEAD fixable near-IR dead
cell staining kit was purchased from Life Technologies (Grand Island, NY). Mouse CpG
DNA was purchased from Hycult Biotech (Canton, MA). All ELISAs were purchased
from BioLegend (San Diego, CA) expect for the IFNα ELISA that was purchased from
PBL assay science (Piscataway Township, NJ).

RNA preparation: RNA was extracted from spleen cells using a TRIzol/RNeasy hybrid
protocol as described previously [15]. Briefly, an appropriate amount of TRIzol was
added to the cells and incubated at room temperature for 30 minutes. Choloroform
(0.2mLs per 1mL of TRIzol) was added and hand shaken for 1 minute. The
choloroform/TRIzol solution rested at room temperature for 3 minutes before being spun
at 4°C for 15 minutes. The clear supernatant was removed and mixed with an equal
volume of cold 70% ethanol. The solution was then added to the Qiagen RNeasy column
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for further purification via the manufactures instructions. DNA was removed using on
column digestion with the Qiagen RNAse free DNase kit. RNA was eluted in RNAse free
water and immediately processed for reverse transcription.
qPCR: 1ug of RNA was reverse transcribed to cDNA using the iScript Reverse
Transcription Supermix (Bio-Rad, Hercules, CA). qPCR was preformed on the CFX
Connect Real-Time system (Bio-rad) using master mixes containing iQ SYBR Green
Supermix (Bio-rad), nuclease free water, primers (10nM) and cDNA. Primers for Mx-1,
Cxcl-10, ISG-15 were synthesized by Integrated DNA Technologies (Coralville, Iowa)
and the IRF-7 and GAPDH primers were purchased from SA Biosciences (Frederick,
MD). The PCR conditions were 3m at 95°C, 40 cycles of 15s at 95°C, 30s at 60°C, 30s at
72°C. Melt curve analysis began at 55°C for 10s and increased every 10s by 0.5°C for 80
cycles. All samples were performed in triplicate, no-cDNA controls were included for
each primer, and melt curve analysis was used to determine if the desired product was
being detected. Expression levels were calculated by comparison to the housekeeping
gene (GAPDH) for each sample with the Bio-Rad CFX manager software.

ISG15 F 5’ CAG AAF CAF ACT CCT TAA TTC 3’
R 5’ AGA-CCT-CAT-ATA-TGT-TGC-TGT-G 3’
Mx-1 F 5’ GAT-CCG-ACT-TCA-CTT-CCA-GAT-GG 3’
R 5’ CAT-CTC-AGT-GGT-AGT-CAA-CCC 3’
Cxcl-10 F 5’ GGA TGG CTG TCC TAG CTC TG
R 5’ TGA GCT AGG GAG GAC AAG GA 3’
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Statistics: Statistical analysis was performed with GraphPad Prism software. Normality
was assessed. If data was normally distributed, a student’s T-test was used. If data was
not normally distributed, a Mann-Whitney analysis was used. Data are expressed as mean
with error bars representing SD.
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